WO2025126079A1

WO2025126079A1 - Wound care compositions and articles thereof having antimicrobial properties

Info

Publication number: WO2025126079A1
Application number: PCT/IB2024/062523
Authority: WO
Inventors: Petra L. KOHLER RIEDI; Rajan B. BODKHE; Amy K. Mcnulty; Kathleen L. DERRICK; Hannah C. COHEN; Kristine M. Kieswetter; Brittni M. SCHIEWER; Li Yu; Joseph J. Stoffel
Original assignee: Solventum Intellectual Properties Co
Current assignee: Solventum Intellectual Properties Co
Priority date: 2023-12-11
Filing date: 2024-12-11
Publication date: 2025-06-19
Anticipated expiration: 2026-06-11

Abstract

Wound care compositions and wound care articles are described herein. Methods of treating wounds with wound care compositions and wound care articles are also described.

Description

WOUND CARE COMPOSITIONS AND ARTICLES THEREOF HAVING ANTIMICROBIAL PROPERTIES BACKGROUND [0001] A wide variety of compositions, materials, and devices are known in the art for use in treating a wound and tissue disruptions. Wounds may be the result of trauma, surgery, or disease and may require measures to control bleeding, absorb wound exudate, ease pain, assist in debridement, and protection from infection or escalating infection. Such measures aim to promote healing and offer protection from further damage. [0002] Wound healing and tissue regeneration are a complicated series of biochemical processes involving four key phases: hemostasis, inflammation, proliferation, and remodeling. If the destructive processes that remove damaged tissues and the repair processes that form new tissue become imbalanced, a chronic non-healing wound may result. Proteases and growth factors regulate this balance. Chronic wounds, which have elevated levels of proteases present within the environment, most often stall in the inflammatory phase, or proceed through repair processes without establishing a sustained anatomic and functional result. [0003] Oxidized celluloses “OCs” such as oxidized regenerated cellulose “ORC” and oxidized non-regenerated cellulose “OnRC” have been used in wound care as hemostatic agents and as healing promoters, especially for chronic wounds since OCs are able to inactivate matrix metalloproteases and bind growth factors. OCs initiate clotting via contact activation by turning to a gelatinous mass. OCs also lower the pH within a wound environment, which is beneficial against microbes, but may induce red cell lysis, interfere with osteogenesis, inactivate thrombin, and ultimately delay healing. pH interference is also a common problem associated with antimicrobial usage. [0004] Infections can prevent wounds from healing and lead to chronic wounds and/or exacerbate existing chronic wounds. If untreated, wound infections can result in tissue loss, systemic infections, septic shock, and death. Bacterial biofilms may also form in a wound, which present further challenges. A biofilm is an association of microorganisms of one or more species that can adhere to a surface forming three-dimensional microbial communities. The microbial communities can have coordinated multi-cellular behavior and produce extracellular polysaccharides that can embed bacteria in a protective matrix that can subvert a host’s defense mechanism and shield bacteria from biocides. Thus, many of the available treatments that are effective against free-living or planktonic bacteria are ineffective against the same bacteria when present in a biofilm. [0005] Treating an infected chronic wound is particularly challenging, especially those that are inoculated with biofilms. What is needed are compositions and articles that aid in the balance of biological processes that support healing. SUMMARY [0006] In one embodiment, a wound care composition is described. The wound care composition includes an oxidized cellulose, a quaternary ammonium salt, a C_8-12 alkyl 1,2-diol, and a water-soluble polymer. [0007] In one embodiment, a wound care article is described. The wound care article includes a wound care composition of the present disclosure, wherein the wound care composition is in the form of a free-standing film or free-standing stack of film. [0008] In one embodiment, an article is described. The wound care article includes: an oxidized cellulose; a quaternary ammonium salt; a C_8-12 alkyl 1,2-diol; and a water-soluble polymer, wherein at least the quaternary ammonium salt, the C_8-12 alkyl 1,2-diol and the water- soluble polymer are in the form of a free-standing film or a free-standing stack of film. [0009] In one embodiment, a method of preparing a wound care article is described. The method includes providing a wound care composition of the present disclosure and applying the wound care composition onto a substrate form a layer and allowing the layer to dry to form a free- standing film. The method optionally further includes forming one or more additional free- standing film and pressing a plurality of free-standing films together to form a free-standing stack of film. [0010] In one embodiment, a method of preparing a wound care article is described. The method includes combining a water-soluble polymer with one or more of a quaternary ammonium salt and a C_8-12 alkyl 1,2-diol to form a composition; coating a substrate with the composition to form a layer; and allowing the layer to dry to form a free-standing stack of film. The method optionally further includes forming one or more additional free-standing film and pressing a plurality of free-standing films together to form a free-standing stack of film. Provided that the free-standing film or the free-standing stack of film comprises the quaternary ammonium salt and the C_8-12 alkyl 1,2-diol and that when the free-standing film or the free-standing stack excludes the oxidized cellulose, the method further includes applying the oxidized cellulose to a surface of the free-standing film or free-standing stack of film. [0011] In one embodiment, a method for treating a wound is described. The method includes contacting a wound with a wound care composition of the present disclosure. [0012] In one embodiment, a method for treating a wound is described. The method includes contacting a wound with a wound care article of the present disclosure. [0013] In one embodiment, a kit is described. The kit includes a wound care composition of the present disclosure and a set of instructions directing a user to contact the wound care composition to a wound. [0014] In one embodiment, a kit is described. The kit includes a wound care article of the present disclosure and a set of instructions directing a user to contact the wound care article to a wound. [0015] In one embodiment, a kit is described. The kit includes a wound care composition of the present disclosure, or components thereof, and a set of instructions directed a user to prepare a wound care article of the present disclosure. BRIEF DESCRIPTION OF DRAWINGS [0016] FIG.1 is an example wound care article of the present disclosure. [0017] FIG.2 is an example wound care article of the present disclosure. [0018] FIG.3 is an example wound care article of the present disclosure. [0019] FIG.4 is an example wound care article of the present disclosure. [0020] FIG.5 is an example wound care article of the present disclosure. [0021] FIG.6 is an example wound care article of the present disclosure. [0022] FIG.7 is an example wound care article of the present disclosure. [0023] FIG.8 is an example wound care article of the present disclosure. DETAILED DESCRIPTION [0024] Described herein are wound care compositions and wound care articles that offer enhanced biofilm kill. The combination of oxidized cellulose, quaternary ammonium salt, and C_8-12 alkyl 1,2-diol in a film-forming water-soluble polymer matrix is shown to synergistically increase efficacy against biofilms of S. aureus and P. aeruginosa. The present disclosure also reveals that the addition of a chelator (e.g., citric acid) can further enhance bioactivity against biofilms; however, chelators are known to negatively impact blood clotting performance in some instances and can even be uncomfortable to some wearers. Thus, it would be favorable to construct a wound dressing that has greater antimicrobial activity without relying on the effects due to the presence of chelators. [0025] Oxidized cellulose, quaternary ammonium salts, and C_8-12 alkyl 1,2-diols have each been individually incorporated into wound care compositions; however, the combination of oxidized cellulose, quaternary ammonium salts, and C_8-12 alkyl 1,2-diols in a single medicament is not known, nor would have one expected the synergistic attributes of such combination. [0026] The wound care compositions and wound care articles of the present disclosure allow for suitable treatment of wounds infected with biofilms and prevent wounds from becoming infected. Definitions [0027] As used herein, “about” means ± 10 percent of a given value. For example, about 10 means 9 to 11. [0028] As used herein, “alkonium salt” refers to a quaternary ammonium salt compound of formula (I): R¹-N⁺(R²)₃ X- (I), wherein R¹ is a C_6-22 alkyl group, and each R² is independently selected from a C_1-22 alkyl group, and X is a pharmaceutically acceptable counterion (e.g., a halide, e.g., Cl, Br, I). [0029] As used herein, “alkyl” refers to a straight or branched hydrocarbon chain. Example alkyl groups include methyl (-CH₃), ethyl (-CH₂CH₃), propyl (-CH₂CH₂CH₃), isopropyl (-CH(CH₃)₂), and the like. [0030] As used herein, “aryl” refers to cyclic group characterized by aromaticity. Aromatic groups are defined by a conjugated planar ring with 4n+2π electrons. Aryl groups do not include heteroatoms within the ring, whereas as heteroaryl groups include at least one heteroatom within the ring, e.g., O, N, or S. [0031] As used herein, “aralkyl” refers to an aryl group substituted with one or more alkyl group. [0032] As used herein, “antiseptic” means an antimicrobial component that kills pathogenic and non-pathogenic microorganisms. Antiseptics generally interfere with cellular metabolism and/or interfere with the cell envelope. Antiseptics are sometimes called disinfectants. Example antiseptics include antimicrobial lipids, phenolic antiseptics, cationic antiseptics, iodine and/or iodophors, peroxide antiseptics, antimicrobial natural oils. [0033] As used herein, “benzalkonium salt” refers to a quaternary ammonium salt compound of the formula (II): PhCH₂N⁺(R³)₃ X- (II), wherein each R³ is independently a C_1-22 alkyl group or a –(CH₂)_m-Y-C(O)-R⁴ group, Y is -O- or -NH-, R⁴ is a C_1-22 alkyl group, m is an integer of 1-6, and X is a pharmaceutically acceptable counterion (e.g., a halide, e.g., Cl, Br, I). “Ph” is

[0034] As used herein, “benzethonium salt” refers to a quaternary ammonium salt compound of formula (III): PhCH₂N⁺(R⁵)₂-(CH₂CH₂O)_n-R⁶ X- (III), wherein each R⁵ is independently a C_1-22 alkyl group, R⁶ is a C_1-22 alkyl group, a C_6-10 aryl group, or a C_7-22 aralkyl group, n is an integer selected from 1-20, and X is a pharmaceutically acceptable counterion (e.g., a halide, e.g., Cl, Br, I). “Ph” is phenyl. [0035] As used herein, “C_8-12 alkyl 1,2-diol” refers to an 8-12 carbon linear or branched alkyl group having two hydroxyl groups (i.e., -OH) – the first hydroxyl group bound to the first carbon and the second hydroxyl group bound the second carbon. A C_8-12 alkyl 1,2-diol is represented by formula (IV): HOCH₂CR⁷(OH)-R⁸ (IV), wherein R⁷ is -H or alkyl and R⁸ is alkyl, so long as R⁷ and R⁸ together contain 6-10 carbons. The term may also be referred to herein as “C_8-12 alkane 1,2-diol” or “1,2-C_8-12 alkanediol.” [0036] As used herein, “chelator” refers to a compound having at least two carboxylic acid groups (i.e., -CO₂H) wherein the oxygen atom of at least one oxygen of a carboxylic acid is 4-6 atoms (e.g., 4-5 atoms) away from an oxygen atom or a nitrogen atom. A “chelator salt” refers to a chelator which has been deprotonated (e.g., -CO₂- Y⁺) and having a pharmaceutically acceptable counterion (e.g., Na⁺, Ca²⁺, or the like). A “chelator compound” refers to a chelator, a chelator salt, or a combination thereof. [0037] As used herein, “collagen” refers to a structural protein found in, for example: (Type I): skin, tendon, vasculature, organs, bone (Type II): cartilage (Type III): reticulate (Type IV): basal lamina, epithelium-secreted layer of the basement membrane (Type V): cell surfaces, hair, and placenta [0038] As used herein, “disinfecting” refers to a reduction in the number of active microorganisms present on a surface being disinfected. Disinfecting may kill or prevent microorganisms from growing or proliferating. [0039] As used herein, “drying” refers to the removal of volatile or vaporizable compounds. When a substance herein is described as “dried,” it means that less than 1 wt.% of said compounds are present. Various methods of drying are known to a skilled artisan. [0040] As used herein, “exclude” means that a component is absent (i.e., present in 0 wt.%). [0041] As used herein, “free-standing construction” or “free-standing film” or “free-standing stack of film” describes an article to which its shape is retained at temperatures less than 80 °C at 1 atm at relative humidity less than 50% for at least 3 months. In other words, the construction is physically stable and does not lose shape by way of melting, swelling, crystallization, phase separation, or the like. Wound care articles of the present disclosure are free-standing constructions. Wound care articles include a dried wound care composition of the present disclosure in which the dried wound care composition is a free-standing film or free-standing stack of film. [0042] As used herein, “microorganism” or “microbe” refers to bacteria, yeast, mold, fungi, protozoa, mycoplasma, and/or viruses including lipid-enveloped RNA and DNA viruses. [0043] As used herein, “oxidized cellulose” or “oxidized celluloses,” abbreviated “OC” and “OCs” respectively, refer to a cellulose wherein at least a portion of its hydroxyl groups have been oxidized to carboxylic acids (i.e., -OH à -CO₂H). Cellulose is a polymeric structural framework of plant cells, with repeating units of d-glucose. Due to the presence of strong hydrogen bonding between polymer chains, cellulose is insoluble in common solvents and in water. Oxidized cellulose is also insoluble in water. The term “oxidized cellulose” encompasses both oxidized non-regenerated cellulose and oxidized regenerated cellulose separately or in combination, unless otherwise specified. Percentages involving oxidized cellulose are intended to be the total amount of oxidized cellulose, whether ORC, OnRC, or the combination thereof. [0044] As used herein, “oxidized non-regenerated cellulose” or “OnRC” refers to a non- regenerated cellulose wherein at least a portion of hydroxyl groups have been oxidized to carboxylic acids (i.e., -OH ^ -CO₂H). [0045] As regenerated cellulose” or “ORC” refers to a regenerated

cellulose hydroxyl groups have been oxidized to carboxylic acids (i.e., -OH ^ -CO₂H). [0046] As used herein, “plasticizer” refers to a substance or combination of substances that lowers the glass transition temperature of another substance (e.g., a pressure-sensitive adhesive). Plasticizers effectively soften, increase flexibility, increase plasticity, decrease viscosity, and/or decrease friction of a substance to which it is added. [0047] As used herein, “polymer” refers to a substance having one or more repeating monomer units. The chemical identities of the polymeric substances herein are at times described in terms of the monomers to which the polymer is derived. A skilled artisan would readily understand the reactivity profile of the recited monomers and how the monomers could synthetically be joined to form the polymer. [0048] As used herein, “preventing” refers to stopping or delaying the onset of a condition within a treated sample relative to an untreated control sample. [0049] As used herein, “regenerated” as it is used in “regenerated cellulose” refers to a process in which natural cellulose (e.g., derived from a natural source such as wood and other agricultural products) undergoes a chemical manufacturing process that breaks down cellulose such that it may solubilized, functionalized, and ultimately “regenerated.” Regenerated celluloses are often called “rayon.” One of such chemical manufacturing processes is called “Viscose Method,” wherein the natural cellulose is treated with a strong base and carbon disulfide to form a xanthate derivative. The xanthate moieties are later removed, thereby “regenerating” the cellulose. Depending upon the selected process, resulting regenerated fibers may imitate the feel and texture of silk, wool, cotton, linen, or the like. As used herein, “non-regenerated” as it is used in “non-regenerated cellulose” refers to the absence of said regenerative processes described above. Regenerated cellulose and non-regenerated cellulose can differ in fiber organization and structure. [0050] When referring to “solubility,” or “to solubilize,” the solubility of a component A in a component B refers to conditions in which only component A and component B are present, e.g., no added salts, compounds, or the like. Furthermore, any solubility values provided herein regard a temperature range of about 20 ⁰C to about 23 ⁰C at atmospheric pressure (i.e., 760 mm/Hg). [0051] As used herein, the term “subject” refers to a mammal, e.g., humans, sheep, horses, cattle, pigs, dogs, cats, rats, mice, and the like. [0052] As used herein, the term “treating” refers to alleviating clinical symptoms of a condition. [0053] As used herein, the term “water-soluble” characterizes a material that dissolves in deionized water at a temperature of 23 °C in an amount of at least 7 wt.% (i.e., 7 g material per 100 g deionized water). A material is considered dissolved if the resulting solution is clear without visible cloudiness, phase separation, or precipitate at 23 °C for 24 h. [0054] As used herein, “water-soluble polymer” refers to polymer that dissolves in deionized water at a temperature of 23 °C in an amount of at least 7 wt.% (i.e., 7 g material per 100 g deionized water). Likewise, a “water-soluble substrate” refers to a material consisting only of a compound(s) (e.g., polymer(s)) which are water-soluble. [0055] As used herein, the term “wound” refers to broken skin, e.g., a cut, a puncture, an abrasion, a scratch, a rash, and the like. A “wound dressing” refers to an article that may control bleeding, absorb wound exudate, ease pain, assist in debriding, protect against infection, mediate infection, modulate proteases, or otherwise promote healing and protection from further damage. A “chronic wound” refers to a wound that does not progress through a normal, orderly, or timely sequence of repair, e.g., a wound that does not heal after 4 weeks of standard care. [0056] As used herein, the term “pyridinium salt” refers to a quaternary ammonium salt of formula V:

(V), wherein R⁹ is a C_4-22 alkyl group and X is a pharmaceutically acceptable counterion (a halide, e.g., Cl, Br, I). [0057] As used herein, the term “quaternary ammonium salt” refers to compound having one or more nitrogen atom substituted with four carbons (i.e., R-N⁺(R)₃), or alternatively a nitrogen is substituted with three carbon groups wherein one carbon shares a double bond with nitrogen (i.e., R=N⁺(R)₂), wherein R is a carbon, e.g., alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, or two R taken together to form a heteroaryl or heterocyclyl. The quaternary ammonium salts of the present disclosure possess antiseptic and/or disinfectant properties. The quaternary ammonium salts of the present disclosure are not characterized by protonated amines, protonated imines, protonated guanidines, or the like, nor are they characterized by groups such as amine oxides. A review of quaternary ammonium salt compounds may be found at Vereshchagin, A. N. Int. J. Mol. Sci. 2021, 22, 6793, the contents of which are incorporated herein by reference in its entirety. [0058] As used herein, the term “volatile” is used to characterize a compound that has a boiling point of no more than 260 °C at 1 atm. Accordingly, “non-volatile” is used to characterize a compound that has a boiling point of less than 260 °C at 1 atm. [0059] FIG.1 is a drawing depicting an example wound care article 100 (or layer thereof) of the present disclosure. Wound care article 100 is shown as a free-standing construction (e.g., one- layer film) having a solubilized oxidized cellulose 102, a quaternary ammonium salt 104, and a C_8-12 alkyl 1,2-diol 105, in a water-soluble polymer 106 (matrix). The selection, arrangement and amounts components are for illustrative purposes. [0060] FIG.2 is a drawing depicting an example wound care article 200 (or layer thereof) of the present disclosure. Wound care article 200 is shown as a free-standing construction (e.g., one- layer film) a solubilized a quaternary ammonium salt 204, and a C_8-12 alkyl 1,2-diol 205 within a water-soluble polymer 206 (matrix), and a discontinuous coating of oxidized cellulose 208 on a surface. The selection, arrangement and amounts components are for illustrative purposes. [0061] FIG.3 is a drawing depicting an example wound care article 300 (or layer thereof) of the present disclosure. Wound care article 300 is shown as a free-standing construction (e.g., one- layer film) having a solubilized oxidized cellulose 302 and a quaternary ammonium salt 304 in a water-soluble polymer 306 (matrix). Wound care article 300 is further shown having a discontinuous coating of oxidized cellulose 308 on a surface. The selection, arrangement and amounts components are for illustrative purposes. [0062] FIG. 4 is a drawing depicting an example wound care article 400 of the present disclosure. Wound care article 400 is shown as a free-standing construction (e.g., one-layer film) having an oxidized cellulose 402, a quaternary ammonium salt 404, a C_8-12 alkyl 1,2-diol 405, and a chelator, a chelator salt, or a combination thereof 410 solubilized within in a water-soluble polymer 406 (matrix). The selection, arrangement and amounts components are for illustrative purposes. [0063] FIG.5 is a drawing depicting an example wound care article 500 (or a layer thereof) of the present disclosure. Wound care article 500 is shown as a free-standing construction (e.g., one-layer film) having an oxidized cellulose 502, a quaternary ammonium salt 504, a C_8-12 alkyl 1,2-diol 505, and a chelator, a chelator salt, or a combination thereof 510 solubilized within in a water-soluble polymer 506 (matrix). Wound care article 500 is further shown having a discontinuous coating of oxidized cellulose 508 on a surface. [0064] FIG. 6 is a drawing depicting an example wound care article 600 of the present disclosure. Wound care article 600 is shown as a free-standing construction (e.g., three-layer film) with a first layer 612 having an oxidized cellulose 602 and a quaternary ammonium salt 604 solubilized within a water-soluble polymer 606 (matrix); a second layer 614 having a quaternary ammonium salt 604, a C_8-12 alkyl 1,2-diol 605, and a chelator, a chelator salt, or a combination thereof 610 solubilized within in a water-soluble polymer 606 (matrix); and a third layer 616 having a quaternary ammonium salt 604, and a chelator, a chelator salt, or a combination thereof 610 solubilized within in a water-soluble polymer 606 (matrix). Wound care article 600 is further shown having a discontinuous coating of oxidized cellulose 608 on a surface. Each layer is shown to be characterized by a thickness t, and the collective layers are shown to be characterized by an overall thickness T. The number of layers and selection, arrangement and amounts of components of each layer are for illustrative purposes. [0065] FIG. 7 is a drawing depicting an example wound care article 700 of the present disclosure. Wound care article 700 is shown as a free-standing construction (e.g., two-layer film) with a first layer 712 and a second layer 714, each shown having a quaternary ammonium salt 704 and a C_8-12 alkyl 1,2-diol 705 solubilized a solubilized within a water-soluble polymer 706 (matrix). Wound care article 700 is further shown having a water-soluble substrate 718 with a discontinuous coating of oxidized cellulose 708 on a surface, wherein the discontinuous coating of oxidized cellulose 708 is in contact with first layer 712. Each layer may be characterized by a thickness t, and the total layers in the stack may be characterized by an overall thickness T (not shown). Likewise, water-soluble substrate 718 is characterized by a thickness th. The number of layers and selection, arrangement and amounts of components of each layer are for illustrative purposes. [0066] FIG.8 is a drawing depicting an example wound care article 800 of the present disclosure. Wound care article 800 is shown as a free-standing construction (e.g., three-layer film) with a first layer 812 having a quaternary ammonium salt 804 and a C_8-12 alkyl 1,2-diol 805 solubilized within in a water-soluble polymer 806 (matrix); second layer 814 having an oxidized cellulose 802 and a quaternary ammonium salt 804, and a chelator, a chelator salt, or a combination thereof 810 solubilized a solubilized within a water-soluble polymer 806 (matrix); and a third layer 816 having a quaternary ammonium salt 804 and a chelator, a chelator salt, or a combination thereof 810 solubilized a solubilized within a water-soluble polymer 806 (matrix). Wound care article 800 is further shown having water-soluble substrates 818 with a discontinuous coating of oxidized cellulose 808 on a surface, wherein the discontinuous coating of oxidized cellulose 808 is in contact with both first layer 812 and third layer 816. Each layer may be characterized by a thickness t, and the collective layers may be characterized by an overall thickness T (not shown). Likewise, each water-soluble substrate 818 may be characterized by a thickness th (not shown). The number of layers and selection, arrangement and amounts of components of each layer are for illustrative purposes. Wound care Compositions [0067] In various embodiments, a wound care composition is described. The wound care composition may include, or consist essentially of, an oxidized cellulose, a quaternary ammonium salt, a C_8-12 alkyl 1,2-diol, and a water-soluble polymer. [0068] In many embodiments, a wound care composition may include, or consist essentially of, an oxidized cellulose; a quaternary ammonium salt; a C_8-12 alkyl 1,2-diol; a water-soluble polymer; and a chelator, a chelator salt, or a combination thereof. [0069] In many embodiments, a wound care composition may include, or consist essentially of, an oxidized cellulose; a benzalkonium chloride; a C_8-12 alkyl 1,2-diol; a water-soluble polymer; and a plasticizer. [0070] In many embodiments, a wound care composition may include, or consist essentially of, an oxidized cellulose; a quaternary ammonium salt; a C_8-12 alkyl 1,2-diol; a water-soluble polymer; and a collagen. [0071] In many embodiments, a wound care composition may include, or consist essentially of, an oxidized cellulose; a quaternary ammonium salt; a C_8-12 alkyl 1,2-diol; a water-soluble polymer; a chelator, a chelator salt, or a combination thereof; and a plasticizer. [0072] In many embodiments, a wound care composition may include, or consist essentially of, an oxidized cellulose; a quaternary ammonium salt; a C_8-12 alkyl 1,2-diol; a water-soluble polymer; a chelator, a chelator salt, or a combination thereof; and a collagen. [0073] In many embodiments, a wound care composition may include, or consist essentially of, an oxidized cellulose; a quaternary ammonium salt; a C_8-12 alkyl 1,2-diol; a water-soluble polymer; a plasticizer; and a collagen. [0074] In many embodiments, a wound care composition may include, or consist essentially of, an oxidized cellulose; a quaternary ammonium salt; a C_8-12 alkyl 1,2-diol; a water-soluble polymer; a chelator, a chelator salt, or a combination thereof; a plasticizer; and a collagen. [0075] In many embodiments, the wound care compositions of the present disclosure may be a dried wound care composition, i.e., the wound care composition includes no greater than 1 wt.% volatile components (e.g., water), e.g., 1 wt.%, 0.8 wt.%, 0.5 wt.%, 0.2 wt.%, 0.1 wt.%, 0.05 wt.%, 0.01 wt.%, or 0 wt.%, or a value within a range between any of the preceding values. In many embodiments, a dried wound care composition may be a wound care article of the present disclosure. Dried wound care composition may be in the form of a free-standing construction. [0076] In many embodiments, the wound care compositions of the present disclosure may further include one or more volatile component present in an amount greater than greater than 1 wt.%. Example volatile components may include water and organic solvents (e.g., ethanol, isopropanol, ethyl acetate, or the like). In some embodiments, a wound care composition may include no greater than 50 wt.% volatile components (e.g., water), e.g., 3 wt.%, 5 wt.%, 10 wt.%, 15 wt.%, 20 wt.%, 25 wt.%, 30 wt.%, 35 wt.%, 40 wt.%, 45 wt.%, or 50 wt.%, or a value within a range between any of the preceding values, e.g., between 20 wt.% and 35 wt.%. Wound care compositions including one or more volatile component may be referred to herein as wet wound care compositions. Wet wound care composition may be in the form of a solution, a dispersion, a colloid, or a suspension. Dry wound care compositions may be in the form of a free-standing construction and may themselves be a wound care article of the present disclosure or combined with other components (e.g., liners, adhesives, or the like) to form a wound care article. [0077] In many embodiments, the wound care compositions of the present disclosure may exclude surfactants. [0078] Further details are described below. Any further details and/or components may be combined. Oxidized Cellulose (“OC”) [0079] Oxidized regenerated cellulose described herein is regenerated cellulose wherein at least a portion of the primary alcohol groups (C6) have been oxidized to carboxylic acid groups. In some embodiments, the regenerated cellulose may be prepared by the viscose or Bemberg process, e.g., rayon that has not been treated with titanium dioxide or similar heavy metal materials. In some embodiments, the regenerated cellulose may have a uniform filament diameter and a denier of about 1-9 (e.g., 1-3). In some embodiments, the regenerated cellulose may be characterized by a degree of polymerization of about 200 to about 500 units. The degree of polymerization (D.P.) of a cellulosic material may be determined by the method described by R. L. Mitchell, Industrial and Engineering Chemistry, vol.45, p.2520 (1953), the contents of which are incorporated herein by reference in its entirety. Oxidized non-regenerated cellulose described herein is also likewise oxidized but has not undergone regenerative processes. As used throughout, “oxidized cellulose” includes oxidized regenerated cellulose, oxidized non-regenerated cellulose, or a combination thereof. [0080] In some embodiments, the oxidation of a regenerated cellulose may be characterized by a carboxyl content of about 5-50% (i.e., 5-50% of the hydroxyl groups have been oxidized to carboxylic acids), e.g., 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50% carboxylated, or a value within a range between any of the preceding values. In some embodiments, the oxidation of a regenerated cellulose may have a carboxyl content of about 12-25 wt.% (e.g., 18-22 wt.%). Lower denier materials may be satisfactorily absorbable at a carboxyl content of only 12-13 wt.% whereas higher denier materials may be slowly absorbable at this level of oxidation. The carboxyl content may be measured according to United States Pharmacopeia (USP23-NF18), as exemplified in Wu, Y. et al Carbohydrate Polymers 2012, 88, 1023-1032, the contents of which are incorporated herein by reference in its entirety. In some embodiments, the oxidized regenerated cellulose of the present disclosure may be prepared according to a process described in U.S. Pat. No. 3,364,200 or U.S. Pat. No. 3,122,479, the contents of each of which are incorporated herein by reference in their entireties. The described oxidized regenerated cellulose at least partly disintegrates, degrades, or dissolves upon exposure to physiological fluids or process such that at least a portion of the material may be absorbed or assimilated at a wound site. [0081] In many embodiments, the oxidized cellulose is present within the composition as dispersed powder/particulates, rather than in the form of knitted, woven, or otherwise fibrous sheet-like structures. In some embodiments, dispersed oxidized cellulose may involve dispersion throughout the composition (see, e.g., FIG. 1) and/or may involve a dispersion of powder/particulates on a surface of other composition components (see, e.g., FIG.2). [0082] In some embodiments, the oxidized cellulose may be present in an amount of about 0.5 wt.% to about 20 wt.% with respect to the weight of the wound care composition (wet or dry). For example, the oxidized cellulose may be present in an amount, in wt.%, of about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or a value within a range between any of the preceding values, e.g., between about 5 and about 8, between about 2 and 6, or the like. Further for example, a wound care composition having 7 wt.% ORC prior to the removal of 30 wt.% volatile components (e.g., water) may have about 10 wt.% ORC in a dried wound care composition. [0083] In some embodiments, the oxidized cellulose may be present in a wt.% ratio (w/w) with respect to an amount of quaternary ammonium salt (e.g., any quaternary ammonium salt described herein, e.g., benzalkonium salt) present in the wound care composition of about 1:1 to about 2000:1. For example, the amount of oxidized cellulose present relative to the amount of quaternary ammonium salt present, in w/w, may be about 1:1, 5:1, 10:1, 15:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, 55:1, 60:1, 70:1, 75:1, 80:1, 85:1, 90:1, 100:1, 110:1, 120:1, 130:1, 140:1, 150:1, 160:1, 170:1, 180:1, 190:1, 200:1, 220:1, 240:1, 260:1, 280:1, 300:1, 325:1, 350:1, 375:1, 400:1, 500:1, 750:1, 1000:1, 1250:1, 1500:1, 1750:1, or 2000:1 or a value within a range between any of the preceding values, e.g., between about 50:1 and about 120:1, between about 30:1 and about 80:1, or the like. [0084] In some embodiments, the oxidized cellulose may be present in a wt.% ratio (w/w) with respect to the amount of water-soluble polymer (any water-soluble polymer described herein, e.g., polyvinyl pyrrolidone) present in the wound care composition of about 1:0.75 to about 1:70. For example, the amount of oxidized cellulose present relative to the amount of water-soluble polymer present, in w/w, may be about 1:0.75, 1:1, 1:2, 1:5, 1:7, 1:10, 1:15, 1:18, 1:20, 1:22, 1:25, 1:28, 1:30, 1:32, 1:35, 1:38, 1:40, 1:42, 1:45, 1:48, 1:50, 1:52, 1:55, 1:58, 1:60, 1:62, 1:65, 1:68, or 1:70, or value within a range between any of the preceding values, e.g., between about 1:20 and about 1:30, between about 1:25 and about 1:40, or the like. [0085] In many embodiments, the oxidized cellulose may be oxidized regenerated cellulose. [0086] In many embodiments, the oxidized cellulose may be oxidized non-regenerated cellulose. [0087] In some embodiments, the oxidized cellulose may be a combination of oxidized regenerated cellulose and oxidized non-regenerated cellulose. Quaternary ammonium salts [0088] In many embodiments, the quaternary ammonium salt may be selected from one or more alkonium salt, one or more benzalkonium salt, one or more benzethonium salt, one or more pyridinium salt, and a combination thereof. [0089] In some embodiments, the quaternary ammonium salt may be an alkonium salt of formula Ia: R¹-N⁺(CH₃)₂R² X- (Ia), wherein R¹ may be a C_6-22 alkyl, e.g., a C₆, C₇, C₈, C₉, C₁₀, C₁₁, C₁₂, C₁₃, C₁₄, C₁₅, C₁₆, C₁₇, C₁₈, C₁₉, C₂₀, C₂₁, or C₂₂ alkyl, or a range between any of the preceding values, e.g., a C_12-16 alkyl, a C_8- ₁₈ alkyl, or the like; R² may be a C_1-22 alkyl, e.g., a C₁, C₂, C₃, C₄, C₅, C₆, C₇, C₈, C₉, C₁₀, C₁₁, C₁₂, C₁₃, C₁₄, C₁₅, C₁₆, C₁₇, C₁₈, C₁₉, C₂₀, C₂₁, or C₂₂ alkyl, or a range between any of the preceding values, e.g., a C_1-6 alkyl, a C_1-4 alkyl, or the like; and X is Cl, Br, or I. [0090] In some embodiments, the quaternary ammonium salt may be an alkonium salt of formula (Ib): R¹-N⁺(CH₃)₃ X- (Ib), wherein R¹ may be a C_6-22 alkyl, e.g., a C₆, C₇, C₈, C₉, C₁₀, C₁₁, C₁₂, C₁₃, C₁₄, C₁₅, C₁₆, C₁₇, C₁₈, C₁₉, C₂₀, C₂₁, or C₂₂ alkyl, or a range between any of the preceding values, e.g., a C_12-16 alkyl, a C_8- ₁₈ alkyl, or the like; and X is Cl, Br, or I. [0091] In some embodiments, the quaternary ammonium salt may be an alkonium salt of the formula: .

[0092] In some quaternary may an alkonium salt of the formula:

. [0093] In many embodiments, the quaternary ammonium salt may be a benzalkonium salt selected from one or more compound of the formula (IIa):

(IIa), wherein n may be an integer from 1-22, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18, or a range between any of the preceding values, e.g., 8-18, 10-16, or the like; and X may be Cl, Br, or I. In some embodiments n may be selected from an integer of 8, 10, 12, 14, 16, or 18. In some embodiments the composition may include one or more benzalkonium chloride of formula IIa. For example, the wound care composition may include a mixture of benzalkonium salts wherein n is 8, 10, 12, 14, 16, and 18. [0094] In some embodiments, the quaternary ammonium salt may be a benzalkonium salt of formula IIb: PhCH₂N⁺(CH₃)₂-(CH₂)_m-NH-C(O)-R⁴ X- (IIb), wherein R⁴ may be a C_4-22 alkyl group, e.g., C₄, C₅, C₆, C₇, C₈, C₉, C₁₀, C₁₁, C₁₂, C₁₃, C₁₄, C₁₅, C₁₆, C₁₇, C₁₈, C₁₉, C₂₀, C₂₁, or C₂₂ alkyl, or a range between any of the preceding values, e.g., a C_13- ₁₇ alkyl, a C_10-18 alkyl, or the like; m may be an integer of 2-4; and X may be Cl, Br, or I. “Ph” is phenyl. [0095] In some embodiments, the quaternary ammonium salt may be a benzalkonium salt of the formula: . [0096] In

a benzethonium salt selected from one or more compound of formula (IIIa): PhCH₂N⁺(CH₃)₂(CH₂CH₂O)_n-R⁶ X- (IIIa), wherein R⁶ may be Ph or -Ph-R¹⁰, R¹⁰ may be a C_4-10 alkyl, n may be an integer selected from 1- 6, and X may be Cl, Br, or I. “Ph” is phenyl or phenylene. [0097] In some embodiments, the quaternary ammonium salt may be a benzethonium salt of the formula: . [0098] In some

be a pyridinium salt of formula IVa: , wherein R⁹ may be a C_4-22 alkyl, e.g., C₄, C₅, C₆, C₇, C₈, C₉, C₁₀, C₁₁, C₁₂, C₁₃, C₁₄, C₁₅, C₁₆, C₁₇, C₁₈, C₁₉, C₂₀, C₂₁, or C₂₂ alkyl, or within a range of any of the preceding values, e.g., a C_12-18 alkyl, a C_10-16 alkyl, or the like; and X may be Cl or Br. [0099] In some embodiments, the quaternary ammonium salt may be a pyridinium salt of formula: .

[00100] In some embodiments, the quaternary ammonium salt (e.g., benzalkonium chloride) may be present in an amount of about 0.01 wt.% to about 1 wt.% with respect to the weight of the wound care composition (wet or dry). For example, the quaternary ammonium salt may be present in an amount, in wt.%, of about 0.01, 0.02, 0.03, 0.04, 0.05, 0.1, 0.13, 0.15, 0.18, 0.2, 0.23, 0.25, 0.28, 0.3, 0.32, 0.35, 0.38, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, or 1.0, or a value within a range between any of the preceding values, e.g., between about 0.05 and about 0.5, between about 0.7 and about 0.9, or the like. Further for example, a wound care composition having 0.13 wt.% quaternary ammonium salt prior to the removal of 30 wt.% volatile components (e.g., water) may have about 0.18 wt.% quaternary ammonium salt in a dried wound care composition. [00101] In some embodiments, the quaternary ammonium salt (e.g., benzalkonium salt) may be present in a wt.% ratio (w/w) with respect to the amount of water-soluble polymer (any water- soluble polymer described herein, e.g., polyvinyl pyrrolidone) present in the wound care composition of about 1:15 to about 1:7000. For example, the amount of quaternary ammonium salt present relative to the amount of water-soluble polymer present, in w/w, may be about 1:15, 1:25, 1:50, 1:75, 1:100, 1:150, 1:200, 1:250, 1:300, 1:350, 1:400, 1:450, 1:500, 1:550, 1:600, 1:650, 1:700, 1:750, 1:800, 1:850, 1:900, 1:950, 1:1000, 1:1250, 1:3000, 1:3500, 1:4000, 1:4500, 1:5000, 1:5500, 1:6000, 1:6500, or 1:7000, or a value within a range between any of the preceding values, e.g., between about 1:200 and about 1:400, between about 1:500 and about 1:750, or the like. [00102] In many embodiments, the wound care composition may exclude other antiseptic compounds, such as polyhexamethylene biguanide (“PHMB”), iodine, chlorhexidine, silver salts, or the like. C_8-12 alkyl 1,2-diol [00103] In some embodiments, the C_8-12 alkyl 1,2-diol may be 1,2-octanediol, (i.e., R⁷ is H and R⁸ is linear C₆ alkyl). [00104] In some embodiments, the C_8-12 alkyl 1,2-diol (e.g., 1,2-octanediol) may be present in an amount of about 0.1 wt.% to about 5 wt.% with respect to the weight of the wound care composition (wet or dry). For example, the C_8-12 alkyl 1,2-diol may be present in an amount (wt.%) of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1,1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.2, 2.5, 2.8, 3.0, 3.2, 3.5, 3.8, 4.0, 4.2, 4.5, 4.8, or 5.0, or a value within a range between any of the preceding values, e.g., between about 0.7 and about 1.0, or the like. Further for example, a wound care composition having 0.7 wt.% C_8-12 alkyl 1,2-diol prior to the removal of 30 wt.% volatile components (e.g., water) may have about 1 wt.% C_8-12 alkyl 1,2-diol in a dried wound care composition. [00105] In some embodiments, a C_8-12 alkyl 1,2-diol (e.g., 1,2-octanediol) may be present in a wt.% ratio (w/w) with respect to an amount of oxidized cellulose of about 1:0.2 to about 1:200. For example, a wt.% ratio of C_8-12 alkyl 1,2-diol to oxidized cellulose may be about 1:0.2, 1:0.5, 1:0.8, 1:1, 1:2, 1:3:, 1:3.2, 1:3.5, 1:3.8, 1:4, 1:4.2, 1:4.5, 1:4.8, 1:5, 1:5.2, 1:5.5, 1:5.8, 1:6, 1:6.2, 1:6.5, 1:6.8, 1:7, 1:7.2, 1:7.5, 1:7.8, 1:8, 1:8.2, 1:8.5, 1:8.8, 1:9, 1:9.2, 1:9.5, 1:9.8, 1:10, 1:25, 1:50, 1:75, 1:100, 1:125, 1:150, 1:175, or 1:200, or a value within a range between any of the preceding values, e.g., between about 1:4 and about 1:8, or the like. [00106] In some embodiments, a C_8-12 alkyl 1,2-diol (e.g., 1,2-octanediol) may be present in a wt.% ratio (w/w) with respect to an amount of quaternary ammonium salt (any quaternary ammonium salt described herein, e.g., benzalkonium salt) of about 500:1 to about0.1:1. For example, a wt.% ratio of C_8-12 alkyl 1,2-diol to quaternary ammonium salt may be about 500:1, 450:1, 400:1, 350:1, 300:1, 250:1, 200:1, 150:1, 100:1, 50:1, 40:1, 30:1, 20:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 0.9:1, 0.8:1, 0.7:1, 0.6:1, 0.5:1, 0.4:1, 0.3:1, 0.2:1, or 0.1:1, or a value within a range between any of the preceding values, e.g., between about 5:1 and about 1:1, between about 0.2:1 to about 0.5:1, or the like. [00107] In some embodiments, a C_8-12 alkyl 1,2-diol (e.g., 1,2-octanediol) may be present in a wt.% ratio (w/w) with respect to an amount of water-soluble polymer (any water-soluble polymer described herein, e.g., polyvinyl pyrrolidone) of about 1:3 to about 1:700. For example, a wt.% ratio of C_8-12 alkyl 1,2-diol to water-soluble polymer may be about 1:3, 1:5, 1:10, 1:15, 1:20, 1:25, 1:26, 1:27, 1:28, 1:29, 1:30, 1:31, 1:32, 1:33, 1:34, 1:35, 1:36, 1:37, 1:38, 1:39, 1:40, 1:50, 1:75, 1:100, 1:125, 1:150, 1:200, 1:250, 1:300, 1:350, 1:400, 1:450, 1:500, 1:550, 1:600, 1:650, or 1:700, or a value within a range between any of the preceding values, e.g., between about 1:30 and about 1:35, or the like. [00108] In some embodiments, a C_8-12 alkyl 1,2-diol (e.g., 1,2-octanediol) may be present in a wt.% ratio (w/w) with respect to an amount of a chelator, a chelator salt, or a combination thereof (any chelator / salt described herein, e.g., citric acid and sodium citrate) of about 1:0.02 to about 1:300. For example, a wt.% ratio of C_8-12 alkyl 1,2-diol to a chelator, a chelator salt, or a combination thereof may be about 1:0.02, 1:0.05, 1:0.1, 1:0.2, 1:0.3, 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:5, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, 1:20, 1:21, 1:22, 1:23, 1:24, 1:25, 1:26, 1:27, 1:28, 1:29, 1:30, 1:40, 1:50, 1:75, 1:100, 1:125, 1:150, 1:175, 1:200, 1:225, 1:250, 1:275, or 1:300, or a value within a range between any of the preceding values, e.g., between about 1:15 and about 1:20, or the like. Water-soluble polymer [00109] In many embodiments, the water-soluble polymer may be characterized by a glass transition temperature (“T_g”) of at least 20 °C. In some embodiments, the water-soluble polymer may be characterized by T_g of no greater than 180 °C. For example, the water-soluble polymer may be characterized by a T_g (°C) of 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, or 180, or a value within a range between any of the preceding values, e.g., between 50 and 90, between 30 and 120, or the like. [00110] In many embodiments, the water-soluble polymer may be characterized by being charge neutral, i.e., absent of salts. [00111] In many embodiments, the water-soluble polymer may be selected from polyvinyl pyrrolidone, polyvinyl alcohol, polyvinyl acetate, polyacrylic acid, polyacrylamide, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, guar gum, hydroxypropyl guar gum, and butenediol vinyl alcohol, and a combination thereof. In some embodiments, the water-soluble polymer may consist essentially of polyvinyl pyrrolidone. In other embodiments, the water-soluble polymer may consist essentially of polyvinyl alcohol. [00112] In some embodiments, the water-soluble polymer (e.g., polyvinyl pyrrolidone) may be present in an amount of about 15 wt.% to about 70 wt.% with respect to the weight of the wound care composition (wet or dry). For example, the water-soluble polymer may be present in an amount, in wt.%, of about 15, 18, 20, 22, 25, 28, 30, 32, 35, 38, 40, 42, 45, 48, 50, 52, 55, 58, 60, 62, 64, 65, 68, or 70, or a value within a range between any of the preceding values, e.g., between about 20 and about 40, between about 30 and about 55, or the like. Further for example, a wound care composition having 40 wt.% water-soluble polymer prior to the removal of 30 wt.% volatile components (e.g., water) may have about 57 wt.% water-soluble polymer in a dried wound care composition. [00113] In some embodiments, the water-soluble polymer may exclude polysaccharides other than the oxidized cellulose. Chelator Compound(s) [00114] In many embodiments, the wound care composition may further include a chelator, a chelator salt, or a combination thereof. In other embodiments, the wound care composition may exclude a chelator, a chelator salt, or a combination thereof. [00115] In some embodiments, a chelator may be characterized by a molecular weight of less than about 500 g/mol. For example, a chelator may be characterized by a molecular weight about 90 g/mol to about 500 g/mol, e.g., 90, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340, 360, 380, 400, 420, 440, 460, 480, 500, or a value between any of the preceding values. A chelator salt thereof will have a molecular weight greater than its corresponding non-salt form. [00116] In some embodiments, a chelator salt may include a counterion selected from Na⁺, K⁺, Cs⁺, Mg²⁺, Ca²⁺, or a combination thereof. [00117] In some embodiments, a chelator may be selected from citric acid, tartaric acid, succinic acid, ethylenediaminetetraacetic acid (“EDTA”), malic acid, oxalic acid, glutaric acid, glutamic acid, maleic acid, phthalic acid, pyromellitic acid, and a combination thereof. In some embodiments, a chelator may be selected from citric acid, tartaric acid, succinic acid, ethylenediaminetetraacetic acid (“EDTA”), and a combination thereof. In some embodiments, a chelator may consist essentially of citric acid. [00118] In some embodiments, a chelator salt may be selected from sodium citrate, sodium tartrate, sodium succinate, sodium calcium edetate, potassium ethylenediaminetetraacetic acid, or a combination thereof. [00119] In some embodiments, the wound care composition may include citric acid and sodium citrate. [00120] In some embodiments, a chelator, chelator salt, or combination thereof (e.g., citric acid, sodium citrate) may be present in an amount of about 0.1 wt.% to about 30 wt.% with respect to the weight of the wound care composition (wet or dry). For example, a chelator may be present in an amount, in wt.%, of about 0.1, 0.2, 0.5, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26, 28, or 30, or a value within a range between any of the preceding values, e.g., between about 3 and about 7, between about 4 and about 10, or the like. Further for example, a wound care composition having 4 wt.% chelator, chelator salt, or combination thereof prior to the removal of 30 wt.% volatile components (e.g., water) may have about 6 wt.% chelator, chelator salt, or combination thereof in a dried wound care composition. [00121] In some embodiments a chelator (e.g., citric acid) may be present in a wt.% ratio (w/w) with respect to an amount of chelator salt (e.g., sodium citrate) present of about 1:0.3 to about 1:3. For example, a chelator and a chelator may be present in a wt.% ratio (w/w) of about 1:0.3, 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.2, 1:1.4, 1:1.6, 1:1.8, 1:2, 1:2.2, 1:2.4, 1:2.6, 1:2.8, or 1:3, or a value within a range between any of the preceding values, e.g., between about 1:1.2 and 1:1.4, or the like. When a chelator and a chelator salt are both present in a wound care composition, the total wt.% of chelator and chelator salt may be no greater than 20 wt.%. In many embodiments, a wt.% ratio (w/w) of chelator and chelator salt may be selected to achieve or maintain a pH of about 2 to about 6, e.g., 2, 3, 4, 5, or 6, or value within a range between any of the preceding values, e.g., between about 2 and about 4. [00122] In some embodiments, a chelator, a chelator salt, or a combination thereof (e.g., citric acid, sodium citrate), may be present in a wt.% ratio (w/w) with respect to an amount of oxidized cellulose of about 1:0.03 to about 1:200. For example, a wt.% ratio of chelator, a chelator salt, or a combination thereof to oxidized cellulose may be about 1:0.03, 1:0.05, 1:0.08, 1:0.1, 1:0.2, 1:0.3, 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.2, 1:1.4, 1:1.6, 1:1.8, 1:2, 1:2.2, 1:2.4, 1:2.6, 1:2.8, 1:3, 1:3.2, 1:3.4, 1:3.6, 1:3.8, 1:4, 1:4.2, 1:4.4, 1:4.6, 1:4.8, 1:5, 1:10, 1:20, 1:30, 1:40, 1:50, 1:75, 1:100, 1:125, 1:150, 1:175, or 1:200, or a value within a range between any of the preceding values, e.g., between about 1:0.8 and 1:1.2, or the like. In some embodiments, a chelator, a chelator salt, or a combination thereof may be present in a wt.% amount less than a wt.% amount of oxidized cellulose present. [00123] In some embodiments, a chelator, a chelator salt, or a combination thereof (e.g., citric acid, sodium citrate), may be present in a wt.% ratio (w/w) with respect to an amount of quaternary ammonium salt (any quaternary ammonium salt described herein, e.g., benzalkonium salt) of about 3000:1 to about 0.1:1. For example, a wt.% ratio of chelator, chelator salt, or a combination thereof to benzalkonium salt may be about 3000:1, 2500:1, 2000:1, 1500:1, 1000:1, 500:1, 250:1, 100:1, 50:1, 25:1, 10:1, 8:1, 6:1, 4:1, 2:1, 1:1, 0.9:1, 0.8:1, 0.7:1, 0.6:1, 0.5:1, 0.4:1, 0.3:1, 0.2:1, or 0.1:1, or value within a range between any of the preceding values, e.g., between about 2:1 and about 1:1, between about 10:1 and about 4:1, or the like. [00124] In some embodiments, a chelator, a chelator salt, or a combination thereof (e.g., citric acid, sodium citrate), may be present in a wt.% ratio (w/w) with respect to an amount of water- soluble polymer (any water-soluble polymer described herein, e.g., polyvinyl pyrrolidone) of about 1:0.5 to about 1:700. For example, a wt.% ratio of chelator, a chelator salt, or a combination thereof to water-soluble polymer may be about 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:2, 1:2.2, 1:2.4; 1:2.6, 1:2.8, 1:3, 1:3.2, 1:3.4; 1:3.6, 1:3.8, 1:4, 1:4.2, 1:4.4; 1:4.6, 1:4.8, 1:5, 1:10, 1:25, 1:50, 1:75, 1:100, 1:150, 1:200, 1:250, 1:300, 1:350, 1:400, 1:450, 1:500, 1:550, 1:600, 1:650, or 1:700, or a value within a range between any of the preceding values, e.g., between about 1:2 and about 1:3, or the like. Plasticizer [00125] In many embodiments, the wound care composition may further include a plasticizer. The plasticizer may be characterized by a boiling point greater than 105 °C and a molecular weight less than 5000 g/mol. For example, a plasticizer may be characterized by a boiling point, on °C, of 110, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340, 360, 380, 400, or more, or a value within a range between any of the preceding values, e.g., between about 280 and about 320, or the like. For example, a plasticizer may be characterized by a molecular weight (g/mol) of 80, 90, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 350, 400, 450, 500, 550, 600, or more, or a value within a range between any of the preceding values, e.g., between about 80 and about 100, or the like. [00126] In some embodiments, the plasticizer may be selected from glycerol, a polyglycerol having 2-20 glycerin units, an esterified polyglycerol (e.g., having a group -OC(O)-R, wherein R is C_1-18 alkyl substituted with at least two -OH), polyethylene oxide, polyethylene glycol, propylene glycol, dipropylene glycol, tripropylene glycol, 2-methyl-1,3-propane diol, sorbitol, pentaerythritol, trimethylol propane, ditrimethylol propane, an ethylene oxide / propylene oxide copolymer, and a combination thereof. In some embodiments, the plasticizer may consist essentially of glycerol. [00127] In some embodiments, a plasticizer (e.g., glycerol) may be present in an amount of about 15 wt.% to about 60% with respect to the weight of the wound care composition (wet or dry). For example, a plasticizer may be present in an amount, in wt.%, of about 15, 18, 20, 22, 25, 28, 30, 32, 35, 38, 40, 42, 45, 48, 50, 52, 55, 58, or 60, or a value within a range between any of the preceding values, e.g., between about 15 and about 30, between about 20 and about 40, or the like. Further for example, a wound care composition having 30 wt.% plasticizer prior to the removal of 30 wt.% volatile components (e.g., water) may have about 43 wt.% chelator, chelator salt, or combination thereof in a dried wound care composition. [00128] In some embodiments, a plasticizer (e.g., glycerol) may be present in a wt.% ratio (w/w) with respect to the amount of oxidized cellulose of about 60:1 to about 0.75:1. For example, a wt.% ratio of plasticizer to oxidized cellulose may be about 60:1.50:1, 40:1, 30:1, 20:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 0.75:1, or a value within a range between any of the preceding values, e.g., between about 10:1 to about 1:1, or the like. [00129] In some embodiments, a plasticizer (e.g., glycerol) may be present in a wt.% ratio (w/w) with respect to an amount of quaternary ammonium salt (any quaternary ammonium salt described herein, e.g., benzalkonium salt) of about 6000:1 to about 15:1. For example, a wt.% ratio of plasticizer to quaternary ammonium salt may be about 6000:1, 5500:1, 5000:1, 4500:1, 4000:1, 3500:1, 3000:1, 2500:1, 2000:1, 1500:1, 1000:1, 900:1, 800:1, 700:1, 600:1, 500:1, 400:1, 300:1, 200:1, 100:1, 95:1, 90:1, 85:1, 80:1, 75:1, 70:1, 65:1, 60:1, 55:1, 50:1, 45:1, 40:1, 35:1, 30:1, 25:1, 20:1, or 15:1, or a value withing a range between any of the preceding values, e.g., between about 40:1 and about 20:1, or the like. [00130] In some embodiments, a plasticizer (e.g., glycerol) may be present in a wt.% ratio (w/w) with respect to an amount of water-soluble polymer (any water-soluble polymer described herein, e.g., polyvinyl pyrrolidone) of about 4:1 to about 0.2:1. For example, a wt.% ratio of plasticizer to water-soluble polymer may be about 4:1, 3.8:1, 3.6:1, 3.2:1, 3:1, 2.8:1, 2.6:1, 2.4:1, 2.2:1, 2:1, 1.8:1, 1.5:1, 1.2:1, 1:1, 0.9:1, 0.8:1, 0.7:1, 0.6:1, 0.5:1, 0.4:1, 0.3:1, or 0.2:1, or a value within a range between any of the preceding values, e.g. between about 1:1 and about 0.6:1, or the like. [00131] In some embodiments, a plasticizer (e.g., glycerol) may be present in a wt.% ratio (w/w) with respect to an amount of a chelator, a chelator salt, or a combination thereof (any chelator / salt described herein, e.g., citric acid, sodium citrate) of about 600:1 to about 0.5:1. For example, a wt.% ratio of plasticizer to chelator, chelator salt, or a combination thereof may be about 600:1, 500:1, 400:1, 300:1, 200:1, 100:1, 75:1, 50:1, 25:1, 20:1, 15:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, or 0.5:1, or a value within a range between any of the preceding values, e.g., between about 10:1 and about 1:1, or the like. [00132] In some embodiments, a plasticizer (e.g., glycerol) may be present in a wt.% ratio (w/w) with respect to an amount of a C_8-12 alkyl 1,2-diol (any C_8-12 alkyl 1,2-diol described herein, e.g., 1,2-octanediol) of about 600:1 to 1.7:1. For example, a wt.% ratio of plasticizer to C_8-12 alkyl 1,2- diol may be about 600:1, 500:1, 400:1, 300:1, 200:1, 100:1, 75:1, 50:1, 40:1, 30:1, 25:1, 20:1, 15:1, 10:18:1, 6:1, 4:1, 2:1, or 1.7:1, or a value within a range between any of the preceding values, e.g., between about 25:1 to about 30:1, or the like. Collagen [00133] Collagen is often used alongside ORC in wound care. Collagen attracts fibroblasts, thereby aiding angiogenesis and debridement. Collagen also supports granulation tissue formation and re-epithelization. [00134] In some embodiments, a wound care composition may further include a collagen. In some embodiments, a collagen may be selected from Type I, Type II, Type III, fragments thereof, and a combination thereof. In some embodiments, a collagen may be chemically modified, for example, an atelocollagen obtained by removing the immunogenic telopeptides from a natural collagen. In some embodiments, a collagen may be, or may include, collagen fragments having a molecular weight of about 5,000 to about 100,000 Daltons, e.g., 5,000, 10,000, 15,000, 20,000, 25,000, 30,000, 35,000, 40,000, 45,000, 50,000, 60,000, 70,000, 80,000, 90,000, 100,000 or a value between any of the preceding values, for example, between about 5,000 and about 50,000, or the like. [00135] In some embodiments, a collagen may be present in an amount of about 1 wt.% to about 60 wt.% with respect to the weight of the wound care composition (wet or dry). For example, a collagen may be present in an amount, in wt.%, of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 25, 28, 30, 35, 40, 45, 50, or 60, or a value within a range between any of the preceding values, e.g., between about 5 and about 8, between about 2 and 6, or the like. In other embodiments, the wound care composition may exclude collagen. [00136] In some embodiments, a collagen may be present in a wt.% ratio (w/w) with respect to an amount of oxidized cellulose of about 60:1 to about 0.15:1. For example, the amount of a collagen present relative to an amount of oxidized cellulose present, in w/w, may be about 60:1, 55:1, 50:1, 45:1, 40:1, 35:1, 30:1, 25:1, 20:1, 15:1, 10:1, 5:1, 4:1, 3:1, 2:1, 1.5:1, 1:1, 0.9:1, 0.8:1, 0.7:1, 0.6:1, 0.5:1, 0.4:1, 0.3:1, 0.2:1, or 0.15:1, or a value between any of the preceding values, e.g., between about 1.5:1 to about 0.2:1, or the like. [00137] In some embodiments, a collagen may be present in a wt.% ratio (w/w) with respect to an amount of quaternary ammonium salt (any quaternary ammonium salt described herein, e.g., benzalkonium salt) present in the wound care composition of about 6000:1 to about 3:1. For example, the amount of collagen present relative to the amount of quaternary ammonium salt present, in w/w, may be about 6000:1, 5000:1, 4000:1, 3000:1, 2000:1, 1000:1, 500:1, 100:1, 90:1, 80:1, 70:1, 60:1, 50:1, 40:1, 30:1, 20:1, 10:1, 8:1, 5:1, or 3:1, or a value within a range between any of the preceding values, e.g., between about 50:1 and about 100:1, between about 30:1 and about 80:1, or the like. [00138] In some embodiments, a collagen may be present in a wt.% ratio (w/w) with respect to the amount of water-soluble polymer (any water-soluble polymer described herein, e.g., polyvinyl pyrrolidone) present in the wound care composition of about 1:1.3 to about 1:23.3. For example, the amount of collagen present relative to the amount of water-soluble polymer present, in w/w, may be about 1:1.3, 1:1.5, 1:1.8, 1:2, 1:5, 1:10, 1:12, 1:15, 1:18, 1:20, 1:22, 1:23.3, or value within a range between any of the preceding values, e.g., between about 1:15 to about 1:20, between about 1:1.5 to about 1:5, or the like. [00139] In some embodiments, a collagen may be present in a wt.% ratio (w/w) with respect to the amount of a chelator, a chelator salt, or a combination thereof (any chelator / salt described herein, e.g., citric acid, sodium citrate) of about 600:1 to 0.03:1. For example, a wt.% ratio of collagen to chelator, a chelator salt, or a combination thereof may be about 600:1, 400:1, 200:1, 100:1, 75:1, 50:1, 25:1, 20:1, 15:1, 10:1, 5:1, 4.8:1, 4.6:1, 4.4:1, 4.2:1, 4:1, 3.8:1, 3.6:1, 3.4:1, 3.2:1, 3:1, 2.8:1, 2.6:1, 2.4:1, 2.2:1, 2:1, 1.8:1, 1.6:1, 1.4:1, 1.2:1, 1:1, 0.9:1, 0.8:1, 0.7:1, 0.6:1, 0.5:1, 0.4:1, 0.3:1, 0.2:1, 0.1:1, 0.09:1, 0.08:1, 0.07:1, 0.06:1, 0.05:1, 0.04:1, or 0.03:1, or a value within a range between any of the preceding values, e.g., between about 1.2:1 and 0.8:1, or the like. [00140] In some embodiments, a collagen may be present in a wt.% ratio (w/w) with respect to an amount of a C_8-12 alkyl 1,2-diol (any C_8-12 alkyl 1,2-diol described herein, e.g., 1,2-octanediol) of about 600:1 to 0.2:1. For example, a wt.% ratio of collagen to C_8-12 alkyl 1,2-diol may be about 600:1, 400:1, 200:1, 100:1, 75:1, 50:1, 30:1, 25;1, 20:1, 15:1, 10:1, 8:1, 5:1, 4:1, 3:1, 2:1, 1:1, 0.9:1, 0.8:1, 0.7:1, 0.6:1, 0.5:1, 0.4:1, 0.3:1, or 0.2:1, or a value within a range between any of the preceding values, e.g., between about 4:1 and about 8:1, or the like. [00141] In some embodiments, a collagen may be present in a wt.% ratio (w/w) with respect to an amount of a plasticizer (any plasticizer described herein, e.g., glycerol) of about 1:0.25 to 1:60. For example, a wt.% ratio of collagen to plasticizer may be about 1:0.25, 1:0.3, 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.91:1, 1:1.2, 1:1.5, 1:1.8, 1:2, 1:2.2, 1:2.5, 1:2.8, 1:3, 1:3.2, 1:3.5, 1:3.8, 1:4, 1:4.2, 1:4.5, 1:4.8, 1:5, 1:5.2, 1:5.5, 1:5.8, 1:6, 1:6.2, 1:6.5, 1:6.8, 1:7, 1:7.2, 1:7.5, 1:7.8, 1:8, 1:8.2, 1:8.5, 1:8.8, 1:9, 1:9.2, 1:9.5, 1:9.8, 1:10, 1:15, 1:20, 1:25, 1:30, 1:35, 1:40, 1:45, 1:50, 1:55, or 1:60, or a value within a range between any of the preceding values, e.g., between about 1:3 to about 1:7, or the like. [00142] In some embodiments, the wound care composition may exclude protein materials other than collagen, if present. [00143] It is to be understood that any combination of components and the recited amounts cannot exceed 100 wt.%. A skilled artisan may readily adjust amounts within the recited ranges to adhere to this notion. [00144] The following wound care compositions may be wet or dry. Wet wound care compositions may further include a volatile component (e.g., water) in an amount of at least 3 wt.%, e.g., 3, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, or a range within any of the preceding values, e.g., between 3 and 35 wt.%, or the like. [00145] In some embodiments, a wound care composition may include, or consist essentially of: the oxidized cellulose present in an amount of about 1 wt.% to about 20 wt.%, or a range described above; the quaternary ammonium salt present in an amount of about 0.01 wt.% to about 1 wt.% (e.g., one or more benzalkonium chloride of Formula IIa above), or a range described above; the water-soluble polymer present in an amount of about 15 wt.% to about 70 wt.% (e.g., polyvinyl pyrrolidone), or a range described above; and the C_8-12 alkyl 1,2-diol present in an amount of about 0.1 wt.% to about 5 wt.% (e.g., 1,2-octane diol), or a range described above. In some embodiments, the oxidized cellulose and the quaternary ammonium salt may be present in a wt.% ratio of 2000:1 to 1:1; the oxidized cellulose and the C_8-12 alkyl 1,2-diol may be present in a wt.% ratio of 200:1 to 0.2:1; and the quaternary ammonium salt and the C_8-12 alkyl 1,2-diol may be present in a wt.% ratio of 1:0.1 to 1:3000. [00146] In some embodiments, a wound care composition may include, or consist essentially of: the oxidized cellulose present in an amount of about 3 wt.% to about 10%; the quaternary ammonium salt present in an amount of about 0.05 wt.% to about 0.5 wt.% (e.g., one or more benzalkonium chloride of Formula IIa above); the water-soluble polymer present in an amount of about 30 wt.% to about 60% (e.g., polyvinyl pyrrolidone); and the C_8-12 alkyl 1,2-diol present in an amount of about 0.5 wt.% to about 2.5 wt.% (e.g., 1,2- octane diol). In some embodiments, the oxidized cellulose and the quaternary ammonium salt may be present in a wt.% ratio of about 6:1 to about 200:1; the oxidized cellulose and the C_8-12 alkyl 1,2-diol may be present in a wt.% ratio of about 1.2:1 to about 10:1; and the quaternary ammonium salt and the C_8-12 alkyl 1,2-diol may be present in a wt.% ratio of 1:50 to about 1:1. [00147] In some embodiments, a wound care composition may include, or consist essentially of: the oxidized cellulose present in an amount of about 1 wt.% to about 20 wt.%; the quaternary ammonium salt present in an amount of about 0.01 wt.% to about 1 wt.% (e.g., one or more benzalkonium chloride of Formula II above); the water-soluble polymer present in an amount of about 15 wt.% to about 70 wt.% (e.g., polyvinyl pyrrolidone); the C_8-12 alkyl 1,2-diol present in an amount of about 0.1 wt.% to about 5 wt.% (e.g., 1,2-octane diol); and a chelator, a chelator salt, or a combination thereof present in an amount of about 0.1 wt.% to about 30 wt.% (e.g., a combination of citric acid and sodium citrate). In some embodiments, the oxidized cellulose and the quaternary ammonium salt may be present in a wt.% ratio of 2000:1 to 1:1; the oxidized cellulose and the C_8-12 alkyl 1,2-diol may be present in a wt.% ratio of 200:1 to 0.2:1; the oxidized cellulose and the chelator and/or chelator salt may be present in a wt.% ratio of 200:1 to 0.03:1; the quaternary ammonium salt and the C_8-12 alkyl 1,2-diol may be present in a wt.% ratio of 1:0.1 to 1:3000; the quaternary ammonium salt and the chelator and/or chelator salt may be present in a wt.% ratio of 1:0.1 to 1:3000; and the C_8-12 alkyl 1,2-diol and the chelator and/or chelator salt may be present in a wt.% ratio of 1:0.02 to 1:300. [00148] In some embodiments, a wound care composition may include, or consist essentially of: the oxidized cellulose present in an amount of about 1 wt.% to 20 wt.%; the quaternary ammonium salt present in an amount of about 0.01 wt.% to 1 wt.%; (e.g., one or more benzalkonium chloride of Formula II above); the water-soluble polymer present in an amount of about 15 wt.% to 70 wt.% (e.g., polyvinyl pyrrolidone); a C_8-12 alkyl 1,2-diol present in an amount of about 0.1 wt.% to 5 wt.% (e.g., 1,2-octane diol); and a chelator, a chelator salt, or a combination thereof present in an amount of about 0.1 wt.% to 30 wt.% (e.g., a combination of citric acid and sodium citrate). In some embodiments, the oxidized cellulose and the quaternary ammonium salt may be present in a wt.% ratio of 1:1 to 2000:1; the oxidized cellulose and the C_8-12 alkyl 1,2-diol may be present in a wt.% ratio of 10:1 to 24:1; the oxidized cellulose and the chelator and/or chelator salt may be present in a wt.% ratio 0.03:1 to 2000:1; the quaternary ammonium salt and the C_8-12 alkyl 1,2-diol may be present in a wt.% ratio of 1:50 to 1:1; the quaternary ammonium salt and the chelator and/or chelator salt may be present in a wt.% ratio of 1:300 to 1:0.1; and the C_8-12 alkyl 1,2-diol and the chelator and/or chelator salt may be present in a wt.% ratio of 1:300 to 1:0.02. Methods of Preparing Wound Care Compositions [00149] In various embodiments, a method for preparing a wound care composition (i.e., wet) of the present disclosure is described. The method may include combining an oxidized cellulose, a quaternary ammonium salt, a water-soluble polymer, and a volatile component (e.g., water). [00150] In some embodiments, the method may further include combining the oxidized cellulose, the quaternary ammonium salt, the water-soluble polymer, and the volatile component with one or more of: a chelator, a chelator salt, or a combination thereof; a plasticizer, and a collagen. [00151] In some embodiments, the method may further include mixing. [00152] In some embodiments, the method may further include removing volatile component(s) (e.g., water) from the wet wound care composition to form a dried wound care composition. The removing of volatile component(s) may include heating (dehydrating), freeze- drying, reduced pressure, or a combination thereof. [00153] In various embodiments, a method for preparing a wound care composition (i.e., dried) of the present disclosure is described. The method may include providing a wet wound care composition of the present disclosure and removing volatile component(s) (e.g., water) from the wet wound care composition to form the dried wound care composition. The removing of volatile component(s) may include heating (dehydrating), freeze-drying, reduced pressure, or a combination thereof. Wound care Articles [00154] In various embodiments, a wound care article is described. The wound care article may include any dried wound care composition of the present disclosure. [00155] In many embodiments, the wound care article may be a free-standing construction. A free-standing construction may involve the dried wound care composition in the form of a free- standing film or a free-standing stack of film. Typically, a single free-standing film may be characterized by a thickness (t) of about 3 mil to about 30 mil. Typically, a free-standing stack of film (i.e., more than one free-standing film pressed together) may be characterized by a thickness (T) of about 6 mil to about 300 mil. [00156] Free-standing constructions produced from non-film counterparts, such as blocks of 6 mil to 300 mil prepared, by dispensing wet wound care compositions into molds and then dried, for example, are encompassed by the present disclosure; however, film constructions are generally better to manufacture and offer the potential for diversification throughout the free-standing construction. [00157] In some embodiments, a wound care article may include a single free-standing film or a free-standing stack of film (i.e., a plurality of free-standing films pressed together). The wound care composition may be contained within a single free-standing film, may be contained within each free-standing film within a free-standing stack of film, or may be distributed in any number of ways throughout a free-standing stack of film. For example, each free-standing film of a free- standing stack of film may include the water-soluble polymer and one or more of the oxidized cellulose; the quaternary ammonium salt; the C_8-12 alkyl 1,2-diol; a chelator, a chelator salt, or a combination thereof; a plasticizer; and a collagen, so long as the free-standing stack of film collectively includes the wound care composition (e.g., see FIGs. 1-8 for illustrations). The selection, amounts, and arrangement of components within a free-standing stack of film can be chosen based on the desired characteristics of article, e.g., increased blood clotting, decreased blood clotting, replenishable antimicrobial at a surface, greater need for inactivating matrix metalloproteinases and binding growth factors, delayed or expedited wound contact of select components, e.g., timed contact, or the like. For example, it may be beneficial to have oxidized cellulose at a surface of a wound care article such that the oxidized cellulose is first to contact a wound and thereby promote clotting more quickly. [00158] In some embodiments, the wound care article may include a free-standing film or free- standing stack of film having the oxidized cellulose present in an amount of about 5 grams per square meter (g/m² or gsm) to about 200 gsm (e.g., within the film(s) and/or coated on the film(s)). For example, the oxidized cellulose may be present in an amount (gsm) of about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 35, 38, 40, 42, 45, 48, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 or a value within a range between any of the preceding values, e.g., between about 6 gsm and about 35 gsm, or the like. In some embodiments, a free-standing film or free-standing stack of film may include at least 6 gsm of oxidized cellulose. In other embodiments, the wound care article may include up to 100 gsm oxidized cellulose, including oxidized cellulose that may be coated upon a free-standing film or free-standing stack of film. For example, a wound care article may include 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100, or a value within a range between any of the preceding values, e.g., between about 35 gsm and about 80 gsm, or the like. Further, the oxidized cellulose may be present in a wt.% ratio relative to any other component as described in the wound care compositions above. [00159] In some embodiments, the wound care article may include a free-standing film or free- standing stack of film having the quaternary ammonium salt (any quaternary ammonium salt of the present disclosure, e.g., benzalkonium salt) present in an amount of about 0.05 gsm to about 1 gsm. For example, the quaternary ammonium salt may be present in an amount (gsm) of about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, or 1, or a value within a range between any of the preceding values, e.g., between about 0.3 gsm and about 0.4 gsm, or the like. Further, the quaternary ammonium salt may be present in a wt.% ratio relative any other component as described in the wound care compositions above. [00160] In some embodiments, the wound care article may include a free-standing film or free- standing stack of film having a C_8-12 alkyl 1,2-diol (any C_8-12 alkyl 1,2-diol of the present disclosure, e.g., 1,2-octanediol) present in an amount of about 1 gsm to about 10 gsm. For example, the C_8-12 alkyl 1,2-diol may be present in an amount (gsm) of about 1, 1.2, 1.5, 1.8, 2, 2.2, 2.5, 2.8, 3, 3.2, 3.5, 3.8, 4, 4.2, 4.5, 4.8, 5, 5.2, 5.5, 5.8, 6, 6.2, 6.5, 6.8, 7, 7.2, 7.5, 7.8, 8, 8.2, 8.5, 8.8, 9, 9.2, 9.5, 9.8, or 10, or a value within a range between any of the preceding values, e.g., between about 2 gsm and about 4 gsm, or the like. Further, the C_8-12 alkyl 1,2-diol may be present in a wt.% ratio relative to any component as described in the wound care compositions above. [00161] In some embodiments, the wound care article may include a free-standing film or free- standing stack of film having a water-soluble polymer (any water-soluble polymer of the present disclosure, e.g., polyvinyl pyrrolidone) present in an amount of about 100 gsm to about 200 gsm. For example, the water-soluble polymer may be present in an amount (gsm) of about 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, or 200, or a value within a range between any of the preceding values, e.g., between about 110 gsm and about 155 gsm, or the like. Further, the water-soluble polymer may be present in a wt.% ratio relative to any component as described in the wound care compositions above. [00162] In some embodiments, the wound care article may include a free-standing film or free- standing stack of film further having a chelator, a chelator salt, or a combination thereof (any chelator / salt of the present disclosure, e.g., citric acid, sodium citrate) present in an amount of about 5 gsm to about 40 gsm. For example, a chelator, a chelator salt, or combination thereof may be present in an amount (gsm) of about 5, 12, 15, 18, 20, 22, 25, 28, 30, 32, 35, 38, or 40, or a value within a range between any of the preceding values, e.g., between about 15 gsm and about 25 gsm, or the like. Further, a chelator, a chelator salt, or a combination thereof may be present in a wt.% ratio relative to any component as described in the wound care compositions above. [00163] In some embodiments, the wound care article may include a free-standing film or free- standing stack of film further having a plasticizer (any plasticizer of the present disclosure, e.g., glycerol) present in an amount of about 50 gsm to about 150 gsm. For example, a plasticizer may be present in an amount (gsm) of about 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150, or a value within a range between any of the preceding values, e.g., between about 110 gsm and about 130 gsm, or the like. Further, a plasticizer may be present in a wt.% ratio relative to any component as described in the wound care compositions above. [00164] In some embodiments, the wound care article may include a free-standing film or free- standing stack of film further having a collagen present in an amount of about 1 gsm to about 25 gsm. For example, a collagen may be present in an amount (gsm) of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 18, 20, 22, or 25, or a value within a range between any of the preceding values, e.g., between about 3 gsm and about 5 gsm, or the like. Further, a collagen may be present in a wt.% ratio relative to any component as described in the wound care compositions above. [00165] In some embodiments, a wound care article may include a free-standing film or free- standing stack of film having, or consisting essentially of: an oxidized cellulose present in an amount of about 5 gsm to 200 gsm, or a range stated above; a quaternary ammonium salt present in an amount of about 0.05 gsm to 1 gsm (e.g., one or more benzalkonium chloride of Formula IIa above), or a range stated above; a C_8-12 alkyl 1,2-diol present in an amount of about 1 gsm to 10 gsm (e.g., 1,2-octane diol), or a range stated above, and a water-soluble polymer present in an amount of about 100 gsm to 200 gsm (e.g., polyvinyl pyrrolidone), or a range stated above. [00166] In some embodiments, a wound care article may include a free-standing film or free- standing stack of film having, or consisting essentially of: an oxidized cellulose present in an amount of about 5 gsm to 200 gsm, or a range stated above; a quaternary ammonium salt present in an amount of about 0.05 gsm to 1 gsm (e.g., one or more benzalkonium chloride of Formula IIa above), or a range stated above; a C_8-12 alkyl 1,2-diol present in an amount of about 1 gsm to 10 gsm (e.g., 1,2-octane diol), or a range stated above, a water-soluble polymer present in an amount of about 100 gsm to 200 gsm (e.g., polyvinyl pyrrolidone), or a range stated above, and one or more of: a chelator, a chelator salt, or a combination thereof present in an amount of about 5 gsm to 40 gsm (e.g., citric acid, sodium citrate), or a range stated above, a plasticizer present in an amount of about 50 gsm to 150 gsm (e.g., glycerol), and a collagen present in an amount of about 1 gsm to 25 gsm. [00167] In some embodiments, a wound care article may include: an oxidized cellulose present in an amount of about 5 gsm to 100 gsm, or a range stated above; a quaternary ammonium salt present in an amount of about 0.05 gsm to 1 gsm (e.g., one or more benzalkonium chloride of Formula IIa above), or a range stated above; a C_8-12 alkyl 1,2-diol present in an amount of about 1 gsm to 10 gsm (e.g., 1,2-octane diol), or a range stated above, and a water-soluble polymer present in an amount of about 100 gsm to 200 gsm (e.g., polyvinyl pyrrolidone), or a range stated above. [00168] In some embodiments, a wound care article may include: an oxidized cellulose present in an amount of about 5 gsm to 100 gsm, or a range stated above; a quaternary ammonium salt present in an amount of about 0.05 gsm to 1 gsm (e.g., one or more benzalkonium chloride of Formula IIa above), or a range stated above; a C_8-12 alkyl 1,2-diol present in an amount of about 1 gsm to 10 gsm (e.g., 1,2-octane diol), or a range stated above, a water-soluble polymer present in an amount of about 100 gsm to 200 gsm (e.g., polyvinyl pyrrolidone), or a range stated above, and one or more of: a chelator, a chelator salt, or a combination thereof present in an amount of about 5 gsm to 40 gsm (e.g., citric acid, sodium citrate), or a range stated above, a plasticizer present in an amount of about 50 gsm to 150 gsm (e.g., glycerol), and a collagen present in an amount of about 1 gsm to 25 gsm. [00169] In some embodiments, a wound care article may include a single free-standing film or 2-10 free-standing films within a free-standing stack of film. For example, a wound care article may include 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 free-standing films, or a value within a range of any of the preceding values, e.g., between 4 and 6, between 3 and 7, or the like (see, e.g., FIG.6 and 8 illustrating 3 free-standing films in a free-standing stack of film; FIG.7 illustrating 2 free-standing films in a free-standing stack of film). [00170] In many embodiments, a wound care article may further include a water-soluble substrate. A water-soluble substrate may include, or consist essentially of, a material as described for a water-soluble polymer above, e.g., polyvinyl pyrrolidone, polyvinyl alcohol, or the like. In some embodiments the water-soluble substrate may consist essentially of a polyvinyl pyrrolidine, a polyvinyl alcohol, or a combination thereof. In some embodiments, the water-soluble substrate may consist essentially of a polyvinyl pyrrolidone nonwoven, a polyvinyl pyrrolidone film, or a combination thereof. In some embodiments, the water-soluble substrate may consist essentially of a polyvinyl alcohol nonwoven, a polyvinyl alcohol film, or a combination thereof. In many embodiments, the water-soluble substrate may be in contact with one or more surface of a free- standing film or free-standing stack of film. A water-soluble substrate may typically be included with wound care articles that include a coating (e.g., discontinuous, or continuous) of oxidized cellulose that is in contact with a surface of the free-standing film or free-standing stack of film. In some embodiments, the water-soluble substrate may be characterized by a thickness (th) of about 3 mil to about 150 mil, e.g., 3, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, or 150 mil, or a value within a range between any of the preceding values, e.g., between about 30 mil and about 50 mil, or the like. In some embodiments, the wound care article may include a water-soluble substrate present in an amount of about 50 g/m² to about 400 g/m², e.g., 50, 60, 70, 80, 90, 100, 120, 150, 180, 200, 220, 250, 280, 300. 320, 350, 380, or 400 g/m², of a value within a range between any of the preceding values, e.g., between about 100 g/m² and about 200 g/m². [00171] In many embodiments, the wound care article may be a wound dressing. Methods of Preparing Wound care Articles [00172] In various embodiments, a method of preparing a wound care article of the present disclosure is described. The method may include providing a wound care composition of the present disclosure, coating a substrate with the wound care composition to form a layer, and allowing the layer to dry to form a single free-standing film. The method may optionally further include forming one or more additional free-standing film according to previous steps and pressing the single-free standing film and the one or more additional free-standing film to form a free- standing stack of film. The single free-standing film or the free-standing stack of film being the wound care article or at least a portion of the wound care article. [00173] In some embodiments, a single free-standing film including the wound care composition may be pressed together with one or more additional free-standing film including one or more component of the wound care composition to form a free-standing stack of film. In some embodiments, each of the free-standing films within a free-standing stack of film includes the wound care composition. [00174] In various embodiments, a method of preparing a wound care article of the present disclosure is described. The method may include providing an oxidized cellulose a quaternary ammonium salt, a C_8-12 alkyl 1,2-diol, and a water-soluble polymer; combining the water-soluble polymer with one or more of the oxidized cellulose, the quaternary ammonium salt, and the C_8-12 alkyl 1,2-diol to form a composition; coating a substrate with the composition to form a layer; and allowing the layer to dry to form a single free-standing film. The method may optionally further include forming one or more additional free-standing film according to previous steps; and pressing the single free-standing film and the one or more additional free-standing film together to form a free-standing stack of film. The single free-standing film or the free-standing stack of film must include the quaternary ammonium salt and the C_8-12 alkyl 1,2-diol. In other words, when a wound care article includes only a single free-standing film, the single free-standing film must include both quaternary ammonium salt and C_8-12 alkyl 1,2-diol; however, any given “single” free- standing film need not include both quaternary ammonium salt and C_8-12 alkyl 1,2-diol when combined with one or more additional free-standing film to form a free-standing stack of film so long as the quaternary ammonium salt and the C_8-12 alkyl 1,2-diol are within at least one free- standing film of the free-standing stack of film. When the single free-standing film or the free- standing stack excludes the oxidized cellulose, the method may further include applying the oxidized cellulose to a surface of the single free-standing film or a surface of the free-standing stack of film. The single free-standing film or the free-standing stack of film being the wound care article or at least a portion of the wound care article. This method allows for constructions in which the components of any wound care composition described herein may be distributed throughout a free-standing stack of film in a variety of ways. In other words, it may be beneficial for some areas of the free-standing stack of film to include a higher or lower concentration of any given component than other areas within the free-standing stack of film. [00175] In some embodiments, the method may include forming the single free-standing film with a composition including the quaternary ammonium salt, the C_8-12 alkyl 1,2-diol, and the water- soluble polymer, wherein the oxidized cellulose may be coated on a surface of the single free- standing film. In other embodiments, the method may include forming the single free-standing film with a composition including the oxidized cellulose, the quaternary ammonium salt, the C_8-12 alkyl 1,2-diol, and the water-soluble polymer; optionally a surface of the single free-standing film may be coated with oxidized cellulose. In some embodiments, the composition for forming the single free-standing film may further include one or more of: a chelator, a chelator salt, or a combination thereof; a plasticizer; and a collagen. [00176] In some embodiments, the method may include preparing a plurality of free-standing films and pressing the plurality of free-standing films together to form a free-standing stack of film. Each free-standing film may be formed with a composition including the quaternary ammonium salt, the C_8-12 alkyl 1,2-diol, and the water-soluble polymer, wherein the oxidized cellulose may be coated on a surface of the free-standing stack of film. In other embodiments, each free-standing film may be formed with a composition including the oxidized cellulose, the quaternary ammonium salt, the C_8-12 alkyl 1,2-diol, and the water-soluble polymer (i.e., the wound care composition); optionally a surface of the free-standing stack of film may be coated with oxidized cellulose. In some embodiments, the composition may further include one or more of: a chelator, a chelator salt, or a combination thereof; a plasticizer; and a collagen. [00177] In some embodiments, the single free-standing film may include the quaternary ammonium salt, the C_8-12 alkyl 1,2-diol, the water-soluble polymer, and the oxidized cellulose. In some embodiments, each free-standing film within a free-standing stack of film may include the quaternary ammonium salt, the C_8-12 alkyl 1,2-diol, the water-soluble polymer, and the oxidized cellulose. [00178] In some embodiments, the drying of the layer of composition may include heating, freeze-drying, reduced pressure, or a combination thereof. The drying may be effective remove volatile components (e.g., water). [00179] In some embodiments, the applying of oxidized cellulose to a surface of the single free- standing film or the free-standing stack of film may involve a powder-coating technique described herein. A powder-coating technique may provide for an oxidized cellulose coating that is discontinuous. A discontinuous coating of oxidized cellulose may allow for a faster breakdown in a wound environment, if desired. In other embodiments, the applying of the oxidized cellulose to a surface of the sing free-standing fil or the free-standing stack of film may involve a slurry-coating technique described herein. A slurry-coating technique may provide for an oxidized cellulose coating that is continuous. [00180] In other embodiments, the method may further include providing a water-soluble substrate (e.g., a water-soluble polymer described herein) and applying an oxidized cellulose to a surface of the water-soluble substrate to provide an oxidized cellulose coating on the water-soluble substrate. In some embodiments, the applying of the oxidized cellulose to the surface of the water- soluble substrate may involve a powder-coating technique. A powder-coating technique may provide for an oxidized cellulose coating that is discontinuous. The water-soluble substrate having an oxidized cellulose coating may subsequently be pressed to a surface of the single free-standing film or the free-standing stack of film. Employing a water-soluble substrate having an oxidized cellulose coating thereon is intended to be encompassed by, but not required by, the method step of applying oxidized cellulose to a surface of a single free-standing film or a free-standing stack of film. Methods of Using Wound Care Compositions and Articles [00181] In various embodiments, a method of treating a wound is described. The method may include contacting a wound with a wound care composition or a wound care article of the present disclosure. [00182] In various embodiments, a method of promoting blood clotting is described. The method may include contacting a bleeding wound with a wound care composition or a wound care article of the present disclosure. [00183] In various embodiments, a method of reducing the number of microbes in or around a wound is described. The method may include contacting a wound with a wound care composition or a wound care article of the present disclosure. In some embodiments, the microbes may include gram-positive bacteria, gram-negative bacteria, or a combination thereof. In some embodiments, the microbes may include Staphylococcus (e.g., Staphylococcus aureus), Pseudomonas (e.g., Pseudomonas aeruginosa), or a combination thereof. In many embodiments, microbes may be reduced within a biofilm environment. In some embodiments, the method may be effective in preventing the formation of a biofilm. [00184] In many embodiments, a wound may be a chronic wound. [00185] The wound care compositions of the present disclosure may be for use in the manufacture of a wound care article of the present disclosure; may be for use in the manufacture of a medicament for treating a wound; or a combination thereof. [00186] The wound care articles of the present disclosure may be for use in the manufacture of a medicament for treating a wound. Kits [00187] In various embodiments, a kit is described. The kit may include an oxidized cellulose, a quaternary ammonium salt, a C_8-12 alkyl 1,2-diol, and a water-soluble polymer. In some embodiments, the kit may further include one or more: volatile component(s); chelator, chelator salt, or combination thereof; plasticizer; and collagen. The kit may further include instructions directing a user to prepare a wound care composition according to the present disclosure. [00188] In various embodiments, a kit is described. The kit may include a wound care composition of the disclosure. In many embodiments, the kit may further include a set of instructions directing a user to prepare a wound care article of the disclosure by way of any method set forth within the disclosure. [00189] In various embodiments, a kit is described. The kit may include a wound care composition of the present disclosure. In many embodiments, the kit may further include a set of instructions directing a user to contact the wound care composition to a wound of subject. [00190] In various embodiments a kit is described. The kit may include a wound care article of the present disclosure. In many embodiments, the kit may further include a set of instructions directing a user to contact the wound care article to a wound of a subject.

EXAMPLES [00191] Objects and advantages of this disclosure are further illustrated by the following examples, but the materials and amounts thereof recited in these examples, as well as other conditions and details, should not be construed to unduly limit this disclosure. These examples are merely for illustrative purposes only and are not meant to be limiting on the scope of the appended claims. Colony Biofilm Assay and Biofilm Survival Assay Method [00192] Staphylococcus aureus, strain 15981 or Pseudomonas aeruginosa American Type Culture Collection strain 15442 was grown to stationary phase overnight in tryptic soy broth (Becton, Dickenson, and Company, Franklin Lakes, NJ) at 37 °C. The culture was diluted 1 to 10,000 in sterile phosphate-buffered saline and 10 microliters of the diluted suspension was placed in a single drop onto polycarbonate membranes (25 mm diameter, 0.2 micrometer pore size, polycarbonate filter membranes obtained from Sigma Millipore, location) placed on top of tryptic soy agar (TSA) containing 1.5 percent agar (Becton, Dickenson, and Company, Franklin Lakes, NJ). The bacteria were allowed to grow for 24 hours at 37 °C. After the growth period, the filters were aseptically transferred to TSA poured into sterile, polystyrene, 6-well plates. [00193] The bacteria were covered with 20 mm circular disks of the articles described below and incubated for 24 hours at 37 °C. Each sample was tested in triplicate. The membranes covered in bacteria and any remaining wound care article were transferred into 10 mL of Dey/Englay (D/E) neutralizing broth (Becton, Dickenson, and Company, Franklin Lakes, NJ) in a 50 mL conical centrifuge tube. The samples were mixed on a vortex mixer at maximum speed for 1 min and then sonicated for 1 min in a sonicating water bath (Model 2150 from Branson Ultrasonics Corporation, Danbury, CT). The samples were serially diluted 10-fold in sterile phosphate buffered saline and were plated onto AC Petrifilm^TM plates obtained from 3M, St. Paul, MN under trade designation “3M PETRIFILM Aerobic Count Plates”. The 3M PETRIFILM plates were incubated for 36 to 48 hours at 37 °C, the number of surviving colony forming units (CFU) were enumerated, and the average log reduction was calculated by subtracting the average log (CFU/sample) of the treated samples from the average log (CFU/sample) of the untreated samples in the same experiment. Materials Table. Material Source Benzalkonium chloride (supplied as 50% solution in water), a combination of compounds of Formula Novo Nordisk, Bagsværd, Denmark IIa. Collagen (4 mm milled powder) Collagen Solutions, Eden Prairie, MN Citric acid monohydrate Alfa Aesar, Ward Hill, MA Glycerol Cargill, Wazayta, MN Hydrolite 8 (1,2-octanediol) Symrise, Chaska, MN Oxidized regenerated cellulose (powder)* Ethicon, Sommerville, NJ Oxidized non-regenerated cellulose (OKCEL F^TM) Synthesia, Czech Republic Polyvinyl alcohol (PVOH) film (CS35) Aicello, Princeton, NJ Polyvinyl alcohol (PVOH) nonwoven (NW) (_S4-40) ^{Kuraray, Osaka, Japan} Polyvinyl pyrrolidone K30 (PVP K30) Ashland, Covington, KY Polyvinyl pyrrolidone K60 (PVP K60, 47% in w_ater)) ^{Ashland, Covington, KY} Promogran^TM Matrix wound dressing material 3M, St. Paul, MN (1.2:1 ORC:Collagen) * Sodium citrate dihydrate Spectrum Chemicals, Gardena, CA Collagen same composition in Promogran^TM * ORC same composition in Promogran^TM Examples 1-3 and Comparative Examples 1-2 [00194] Examples 1-3: the following was combined in a MAX 100 cup (Flacktec Inc.; Landrum, SC) and mixed at 3500 rpm for 1 min using a DAC 400 FVZ SpeedMixer^TM (Flacktec, Inc.) in the amounts specified in Table 1A: glycerol, BAC (supplied as a 50% solution in water), Hydrolite 8, deionized water (added), citric acid, and sodium citrate. Subsequently, ORC (or milled Promogran^TM) and PVP K30 (100% solids) or PVP K60 (47% in water), in the amounts according to Table 1A, were added to the MAX 100 cup and the resulting mixture was mixed for an additional minute at 3500 rpm. The wet compositions were knife-coated onto a release liner at a gap of 254 microns (i.e., 10 mill; wet thickness about 1/2 of gap; dried thickness about 4 mil and a basis weight of 100 g/m²). The wet compositions were dried at 80 °C for 20 min in a convection oven. The resulting dry films were flexible and were removed from the release liner as a free- standing film (i.e., a single “film layer”). Three film layers, each film layer being 100 g per square meter, were stacked together to provide a free-standing stack of film of 300 g/m², as described in the wound care articles of Table 1B. [00195] Comparative Example 1 (CE 1) was prepared in the same manner, void of ORC. Three film layers, each film layer being 100 g per square meter, were stacked together to provide a free-standing stack of film of 300 g/m^2. [00196] Comparative Example 2 (CE 2) was prepared in the same manner, void of ORC and collagen (i.e., void of Promogran^TM). Three film layers, each film layer being 100 g per square meter, were stacked together to provide a free-standing stack of film of 300 g/m². [00197] The pre-dried compositions (i.e., “wet” compositions) of Examples 1-3 and Comparative Examples 1-2 are represented in Table 1A. The wound care articles thereof (i.e., “dried” compositions) are represented in Table 1B. The Colony Biofilm Assay results are shown in Table 1C. Table 1A. Compositions (“wet”) of Examples 1-3 and Comparative Examples 1-2 EX Promogran ORC BAC Hydrolite Citric Sodium Glycerol PVP Water Total (50%in acid citrate K30 added water) (g) (g) (g) (g) (g) (g) (g) (g) (g) (g) CE 1 0.00 0.00 0.17 0.78 2.14 2.85 27.21 33.46 33.39 100 CE 2 0.00 0.00 0.17 0.80 2.18 2.91 25.34 37.49 31.10 100 1 0.00 3.90 0.17 0.78 2.14 2.85 27.21 29.56 33.39 100 2 0.00 7.81 0.17 0.78 2.14 2.85 27.21 25.66 33.39 100 3 4.74 2.17* 0.15 0.69 1.98 2.57 24.11 34.00 29.59 100 * Calculated; provided as component of Promogran^TM Table 1B. Wound care Articles of Examples 1-3 and Comparative Examples 1-2 Example Promogran ORC BAC Hydrolite Citric Sodium Glycerol PVP Total acid citrate K30 gsm gsm gsm gsm gsm gsm gsm gsm gsm CE 1 0 0 0.39 3.51 9.66 12.87 122.67 150.9 300 CE 2 0 0 0.39 3.51 9.51 12.69 110.49 163.44 300 1 0 17.61 0.39 3.51 9.66 12.87 122.67 133.29 300 2 0 35.19 0.39 3.51 9.66 12.87 122.67 115.71 300 3 20.22 9.27 0.33 2.94 8.43 10.95 102.84 144.99 300 * Calculated; provided as component of Promogran^TM Table 1C. Colony Biofilm Assay for Examples 1-3 and CE 1-2 Example LRV Stnd. Dev. (S. aureus) CE 1 1.3 0.73 CE 2 1.6 0.09 1 4.6 0.93 2 5.1 0.98 3 3.1 0.71 Example 4 and Comparative Examples 3-5: Antimicrobial Agent Solubility [00198] To four separate vials containing a mixture of oxidized regenerated cellulose (0.25 g) in water (4 g) was added dropwise an antimicrobial agent of Table 2. White precipitate was observed for all agents except for benzalkonium chloride. Chlorhexidine digluconate, polyhexamethylene biguanide, and octenidine dihydrochloride are not suitable actives alongside oxidized regenerated cellulose since, in theory, said actives complex with oxidized regenerated cellulose and precipitate from solution. Table 2. Solubility of Antimicrobial Agents with ORC. Example Agent Amount Amount Observation solution solids 4 Benzalkonium chloride 0.52g 0.26 g No precipitation (50% in water)¹ CE 3 Chlorhexidine 0.45 g 0.09 g Precipitation digluconate (20% in water)² CE 4 Polyhexamethylene 0.45 g 0.09 g Precipitation biguanide (20% in water)³ CE 5 Octenidine 0.90 g 0.09 g Precipitation dihydrochloride (10% in 1:1 water:methanol)⁴ ¹ NovoNordisk (Bagsvaerd, Denmark) ² Millipore Sigma (Madison, WI) ³ PureCare^TM Unilab Chemicals & Pharmaceuticals (Mumbai, India) ⁴ Alfa Aesar (Tewksbury, MA) Example 5 and Comparative Example 6 [00199] Example 5 and Comparative Example 6 include two film layers, each film layer was prepared using the quantities of the following components: 24.17 g glycerol, 0.16 g BAC (supplied as a 50% solution in water), 0.73 g Hydrolite 8, 6.40 g water, 2.00 g citric acid, and 2.66 g sodium citrate (see Table 3A). The mixture was combined in a MAX 100 cup (Flacktec Inc.; Landrum, SC) and mixed at 3500 rpm for 1 min using 34 a DAC 400 FVZ SpeedMixerTM (Flacktec, Inc.). Subsequently, 63.89 g PVP K60 (47% in water) was added to the MAX 100 cup and the resulting mixture was mixed for an additional minute at 3500 rpm. The compositions were knife-coated onto a release liner at a gap of 254 microns (i.e., 10 mill; wet thickness about 1/2 of gap; dried thickness about 4 mil and a basis weigh of 100 g/m². The composition was dried at 80 °C for 20 min in a convection oven. The resulting free-standing film was flexible and removed from the release liner. Two free-standing films were laminated together using hand pressure to make a free- standing stack of films of 200 g/m² (i.e., each of the two films was 100 g/m²). The free-standing stack of film was powder-coated with oxidized non-regenerated cellulose (“OnRC”) via the direct powder-coating method described below, resulting in 15.3% w/w OnRC. Comparative Example 6 was not coated with OnRC. Direct Coating Method. Powdered OnRC in the form of very small fibers (e.g., fragment size of less than 1 mm) may be dispersed over the top of the free-standing stack of film by hand and gently pressed onto the slightly tacky film. Excess OnRC powder may be removed by turning the film over such that excess OnRC powder falls off. The film may be turned over and powdered OnRC may be applied in the same manner. [00200] Table 3B includes details of the wound care articles. [00201] Table 3C includes biofilm survival data for Example 5 and Comparative Example 6. Table 3A. Compositions (“wet”) for preparing a single film layer for use in Example 5 and Comparative Example 6 EX BAC Hydrolite Citric Sodium Glycerol PVP K60 Water Total (50% in acid citrate (47% in added water) water) (g) (g) (g) (g) (g) (g) (g) (g) 5 0.16 0.73 2.00 2.66 24.35 63.73 6.37 100 CE6 0.16 0.73 2.00 2.66 24.35 63.73 6.37 100 Table 3B. Wound care Articles of Example 5 and Comparative Example 6 EX No. OnRC BAC Hydrolite Citric Glycerol PVP Total film acid / K60 layers citrate gsm gsm gsm gsm gsm gsm gsm 5 2 30.6 0.24 2.06 13.24 68.62 85.24 200 CE6 2 0 0.26 2.44 15.64 81.02 100.64 200 Table 3C. Biofilm log reduction data for Examples 5 and Comparative Example 6 Example Log reduction value Stnd. Dev. (S. aureus) 5 6.2 1.21 CE6 2.9 0.32 Examples 6-8 and Comparative Examples 7-10 [00202] Examples 6-8 and Comparative Example 7-9 were prepared using the quantities provided in Table 4A: glycerol, BAC (supplied as a 50% solution in water), Hydrolite 8 if present, citric acid/sodium citrate if present, and water were added to MAX 100 cup (Flacktec Inc.; Landrum, SC) and mixed at 3500 rpm for 1 min using 34 a DAC 400 FVZ SpeedMixerTM (Flacktec, Inc.). Subsequently, PVP K60 (47% in water) (Ashland) was added to the MAX 100 cup and the resulting mixture was mixed for an additional minute at 3500 rpm. The compositions were knife-coated onto a release liner at a gap of 254 microns (i.e., 10 mill; wet thickness about ½ of gap; dried thickness about 4 mil and a basis weight of 100 g/m². The compositions were dried at 80 °C for 20 min in a convection oven. The resulting free-standing film was flexible and removed from the release liner. Two free-standing films were laminated together using hand pressure to make a free-standing stack of films of 200 g/m² (i.e., each of the two films was 100 g/m²). [00203] Examples 6-8: The free-standing stack of film was powder-coated with oxidized regenerated cellulose (“ORC”) via the direct powder-coating method described below, resulting in 14.7, 13.64, 15.82 %w/w ORC respectively. Direct Coating Method. Powdered ORC in the form of very small fibers (e.g., fragment size of less than 1 mm) may be dispersed over the top of the free-standing stack of film by hand and gently pressed onto the slightly tacky film. Excess ORC powder may be removed by turning the film over such that excess ORC powder falls off. The film may be turned over and powdered ORC may be applied in the same manner. [00204] Comparative Examples 7-9 were not powder-coated with ORC. [00205] Comparative Example 10 was prepared with only ORC, PVP K60, and glycerol. Table 4A. Compositions (“wet”) of Examples 7-9 and Comparative Examples 7-9 EX BAC Hydrolite Citric Sodium Glycerol PVP Water Total (50% in acid citrate K60 added water) (47% in water) (g) (g) (g) (g) (g) (g) (g) (g) CE 7 0.15 0.70 0 0 26.78 70.15 2.22 100 6 0.15 0.70 0 0 26.78 70.15 2.22 100 CE 8 0.15 0.73 2.00 2.66 24.17 63.89 6.40 100 7 0.15 0.73 2.00 2.66 24.17 63.89 6.40 100 CE 9 0.15 0 1.95 2.60 24.74 64.79 5.77 100 8 0.15 0 1.95 2.60 24.74 64.79 5.77 100 CE 10 0 0 0 0 26.78 70.15 3.07 100 Table 4B. Wound care Articles of Examples 7-9 and Comparative Examples 7-9 E_X ^{No. film} l_{ayers ORC BAC Hydrolite} Citric acid /_citrate ^Glycerol PVP K₆₀ ^Total wt.% wt.% wt.% wt.% wt.% wt.% wt.% CE 7 2 0 0.12 1.16 0 44.25 54.47 100 6 2 14.7 0.11 1.2 0 37.53 46.46 100 CE 8 2 0 0.13 1.22 7.81 40.51 50.33 100 7 2 13.64 0.11 1.05 6.74 34.98 43.46 100 CE 9 2 0 0.13 0 7.62 41.35 50.90 100 8 2 15.82 0.11 0 6.41 34.81 42.85 100 CE 10 2 15 0 0 0 32.45 52.55 100 Table 4C. Wound care Articles of Examples 7-9 and Comparative Examples 7-9 E_{X ORC BAC Hydrolite} ^{Citric acid /} c_{itrate Glycerol PVP K60 Total} gsm gsm gsm gsm gsm gsm gsm CE 7 0 0.24 2.32 0 88.5 108.94 200 6 29.4 0.22 2.4 0 75.06 92.92 200 CE 8 0 0.26 2.44 15.62 81.02 100.66 200 7 27.28 0.22 2.1 13.48 69.96 86.92 200 CE 9 0 0.26 0 15.24 82.7 101.8 200 8 31.64 0.22 0 12.82 69.62 85.7 200 CE 10 30 0 0 0 64.9 105.1 200 Table 4D. Biofilm log reduction data for Examples 7-9 and Comparative Examples 7-9 Example Log reduction Stnd. Dev. value (P. aeruginosa) CE 7 0.34 0.19 6 3.16 0.4 CE 8 0.6 0.23 7 6.67 0.19 CE 9 0.24 0.07 8 3.71 0.31 CE 10 0.56 0.33 Other Suitable Coating Methods [00206] The following powder coating techniques are alternative ways to construct the articles of the present disclosure. [00207] Indirect-1 Powder Coating: OC may be deposited onto one or more substrates (e.g., polyvinyl alcohol nonwoven or film) with a vibration feeder (e.g., Eriez Magnetics, Model 20A) at a rate (e.g., 1 m per min) to provide an OC coating thereon. Deionized water may be sprayed onto OC-powdered substrates to bind the OC powder to the substrate. The sprayed water may partially dissolve a portion of the substrate. OC-powdered substrates may be dried for a period (e.g., 24 h) at room temperature (about 21°C at 1 atm) and subsequently pressed together to form a free-standing stack of film. [00208] Indirect-2 Powder Coating: OC may be deposited onto a film liner (e.g., polyethylene terephthalate) with a sift. An aqueous solution of water-soluble polymer (e.g., 10 wt.% PVP K30) may be sprayed onto the deposited OC powder and the resulting constructed dried for a period (e.g., 24 h) at an elevated temperature (e.g., 60 °C). The water-soluble polymer may serve to bind the OC powder. The dried constructions may be subsequently pressed together to form a free-standing stack of film. [00209] Indirect-3 Powder Coating: A film liner (e.g., polyethylene terephthalate) may be placed on top of a substrate (e.g., polyvinyl alcohol nonwoven substrate, polyvinyl alcohol film, or the like) having an OC powder coating thereon. The resulting construction may be calendared by being passed through two heated (e.g., 200 °F, about 93 °C) flat rollers at a pressure (e.g., 100 Psi, about 690 kPa) and at a speed of e.g., 3 ft per min. The calendaring may press the OC powder into the substrate(s) and the film liner may be subsequently removed. OC powdered substrates may be subsequently laminated with hand pressure to a free-standing stack of film. [00210] Indirect-4 Powder Coating: A nonwoven substrate (e.g., polyvinyl alcohol) may be placed on top of a nonwoven substrate (e.g., polyvinyl alcohol) having an OC powder coating thereon. The resulting construction may be calendared by being passed through two heated (e.g., 200 °F, about 93 °C) flat rollers at a pressure (e.g., 100 Psi, about 690 kPa) and at a speed (e.g., 3 ft per min). The nonwovens may become one layer encasing the OC powder. The OC powdered substrate may be subsequently pressed together to form a free-standing stack of film. [00211] Indirect-5 Powder Coating: A film substrate (e.g., polyvinyl alcohol) may be placed on top of a nonwoven substrate (e.g., polyvinyl alcohol) having an OC powder coating thereon. The resulting construction may be calendared by being passed through two heated (e.g., 200 °F, about 93 °C) flat rollers at a pressure (e.g., 100 Psi, about 690 kPa) and at a speed (e.g., 3 ft per min). The film and the nonwoven may become one layer encasing the OC powder. The OC powdered substrates may be subsequently pressed together to form a free-standing stack of film. EQUIVALENTS [00212] Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.

Claims

CLAIMS What is claimed is: 1. A wound care composition comprising: an oxidized cellulose; a quaternary ammonium salt; a C_8-12 alkyl 1,2-diol; and a water-soluble polymer.

2. The wound care composition of claim 1, wherein the oxidized cellulose is characterized by a carboxyl content of 5-50%.

3. The wound care composition of any one of claims 1-2, wherein the oxidized cellulose is present in an amount of about 0.5 wt.% to about 20 wt.% with respect to the weight of the wound care composition.

4. The wound care composition of any one of claims 1-3, wherein the oxidized cellulose is present in a wt.% ratio of about 1:1 to about 2000:1 relative to an amount of quaternary ammonium salt present in the wound care composition.

5. The wound care composition of any one of claims 1-4, wherein the oxidized cellulose is present in a wt.% amount of 1:0.75 to about 1:70 relative to an amount of the water-soluble polymer present in the wound care composition.

6. The wound care composition of any one of claims 1-5, wherein the oxidized cellulose is oxidized regenerated cellulose.

7. The wound care composition of any one of claims 1-5, wherein the oxidized cellulose is oxidized non-regenerated cellulose.

8. The wound care composition of any one of claims 1-5, wherein the oxidized cellulose is a combination of oxidized regenerated cellulose and oxidized non-regenerated cellulose.

9. The wound care composition of any one of claims 1-8, wherein the quaternary ammonium salt is present in an amount of about 0.01 wt.% to about 1 wt.% with respect to the weight of the wound care composition.

10. The wound care composition of any one of claims 1-9, wherein the quaternary ammonium salt is present in a wt.% ratio of 1:15 to about 1:7000 relative to an amount of the water- soluble polymer present in the wound care composition.

11. The wound care composition of any one of claims 1-10, wherein the quaternary ammonium salt is a benzalkonium salt selected from one or more compound of formula IIa: (IIa), wherein n is selected from

12. The wound care composition of any one of claims 1-11, wherein the water-soluble polymer is selected from polyvinyl pyrrolidone, polyvinyl alcohol, polyvinyl acetate, polyacrylic acid, polyacrylamide, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, guar gum, hydroxypropyl guar gum, butene vinyl alcohol, and a combination thereof.

13. The wound care composition of any one of claims 1-12, wherein the water-soluble polymer is present in an amount of about 15 wt.% to about 70 wt.% with respect to the weight of the wound care composition.

14. The wound care composition of any one of claims 1-13, further comprising a chelator, a chelator salt, or a combination thereof.

15. The wound care composition of any one of claims 1-14, further comprising a chelator characterized by a molecular weight of 90 g/mol to 500 g/mol.

16. The wound care composition of any one of claims 1-15, further comprising a chelator selected from citric acid, tartaric acid, succinic acid, ethylenediaminetetraacetic acid (“EDTA”), malic acid, oxalic acid, glutaric acid, glutamic acid, maleic acid, phthalic acid, pyromellitic acid, or a combination thereof.

17. The wound care composition of any one of claims 1-16, further comprising a chelator, a chelator salt, or a combination thereof present in a total amount of about 0.1 wt.% to about 30 wt.% with respect to the weight of the wound care composition.

18. The wound care composition of any one of claims 1-17, further comprising a chelator and a chelator salt present in a wt.% ratio of about 3:1 to about 0.3:1.

19. The wound care composition of any one of claims 1-18, further comprising a chelator, a chelator salt, or a combination thereof present in a wt.% ratio of about 1:0.03 to about 1:200 relative to an amount of oxidized cellulose.

20. The wound care composition of any one of claims 1-19, further comprising a chelator, a chelator salt, or a combination thereof present in a wt.% ratio of about 3000:1 to about 0.1:1 relative to an amount of the quaternary ammonium salt.

21. The wound care composition of any one of claims 1-20, further comprising a chelator, a chelator salt, or a combination thereof present in a wt.% ratio of about 1:0.5 to about 1:700 relative to an amount of the water-soluble polymer.

22. The wound care composition of any one of claims 1-21, wherein the C_8-12 alkyl 1,2-diol is 1,2-octane diol.

23. The wound care composition of any one of claims 1-22, wherein the C_8-12 alkyl 1,2-diol present in an amount of about 0.1 wt.% to about 5 wt.% with respect to the weight of the wound care composition.

24. The wound care composition of any one of claims 1-23, wherein the C_8-12 alkyl 1,2-diol present in a wt.% ratio of about 1:0.2 to about 1:200 relative to an amount of oxidized cellulose.

25. The wound care composition of any one of claims 1-24, wherein the C_8-12 alkyl 1,2-diol present in a wt.% ratio of about 500:1 to about 0.1:1 relative to an amount of the quaternary ammonium salt.

26. The wound care composition of any one of claims 1-25, wherein the C_8-12 alkyl 1,2-diol present in a wt.% ratio of about 1:3 to about 1:700 relative to an amount of the water-soluble polymer.

27. The wound care composition of any one of claims 1-26, wherein the C_8-12 alkyl 1,2-diol and a chelator, a chelator salt, or a combination thereof, wherein the C_8-12 alkyl 1,2-diol is present in a wt.% ratio of about 1:0.02 about 1:300 relative to an amount of the chelator, the chelator salt, or the combination thereof.

28. The wound care composition of any one of claims 1-27, further comprising a plasticizer.

29. The wound care composition of any one of claims 1-28, further comprising a plasticizer characterized by a boiling point greater than 105 °C and a molecular weight less than 5000 g/mol.

30. The wound care composition of any one of claims 1-29, further comprising a plasticizer selected from glycerol, a polyglycerol having 2-20 glycerin units, an esterified polyglycerol, polyethylene oxide, polyethylene glycol, propylene glycol, dipropylene glycol, tripropylene glycol, 2-methyl-1,3-propane diol, sorbitol, pentaerythritol, trimethylol propane, ditrimethylol propane, an ethylene oxide / propylene oxide copolymer, and a combination thereof.

31. The wound care composition of any one of claims 1-30, further comprising a plasticizer present in an amount of about 15 wt.% to about 60 wt.% with respect to the weight of the wound care composition.

32. The wound care composition of any one of claims 1-31, further comprising a plasticizer present in a wt.% ratio of about 60:1 to about 0.75:1 relative to an amount of oxidized cellulose.

33. The wound care composition of any one of claims 1-32, further comprising a plasticizer present in a wt.% ratio of about 6000:1 to about 15:1 to an amount of the quaternary ammonium salt.

34. The wound care composition of any one of claims 1-33, further comprising a plasticizer present in a wt.% ratio of about 4:1 to about 0.2:1 relative to an amount of the water-soluble polymer.

35. The wound care composition of any one of claims 1-34, further comprising a collagen.

36. The wound care composition of any one of claims 1-35, further comprising a collagen selected from Type I, Type II, Type III, fragments thereof, and a combination thereof.

37. The wound care composition of any one of claims 1-36, further comprising a collagen in an amount of about 1 wt.% to about 60 wt.% with respect to the weight of the wound care composition.

38. The wound care composition of any one of claims 1-37, further comprising a collagen present in a wt.% ratio of about 60:1 to about 0.15:1 relative to an amount of oxidized cellulose.

39. The wound care composition of any one of claims 1-38, further comprising a collagen present in a wt.% ratio of about 6000:1 to about 3:1 relative to an amount of the quaternary ammonium salt.

40. The wound care composition of any one of claims 1-39, further comprising a collagen present in a wt.% ratio of about 1:0.75 to about 1:23.3 relative to an amount of the water- soluble polymer.

41. The wound care composition of any one of claims 1-40, further comprising a pH buffer.

42. The wound care composition of any one of claims 1-41, characterized by a pH of 2-6.

43. The wound care composition of any one of claims 1-42, the oxidized cellulose present in an amount of about 1 wt.% to about 20 wt.%; the quaternary ammonium salt present in an amount of about 0.01 wt.% to about 1 wt.%; the water-soluble polymer present in an amount of about 15 wt.% to about 70 wt.%; and the C_8-12 alkyl 1,2-diol present in an amount of about 0.1 wt.% to about 5 wt.%.

44. The wound care composition of any one of claims 1-43, the oxidized cellulose and the quaternary ammonium salt present in a wt.% ratio of 2000:1 to 1:1; the oxidized cellulose and the C_8-12 alkyl 1,2-diol present in a wt.% ratio of 200:1 to 0.2:1; and the quaternary ammonium salt and the C8-12 alkyl 1,2-diol present in a wt.% ratio of 1:0.1 to 1:3000.

45. The wound care composition of any one of claims 1-44, the oxidized cellulose present in an amount of about 3 wt.% to about 10%; the quaternary ammonium salt present in an amount of about 0.05 wt.% to about 0.5 wt.%; the water-soluble polymer present in an amount of about 30 wt.% to about 60%; and the C_8-12 alkyl 1,2-diol present in an amount of about 0.5 wt.% to about 2.5 wt.%.

46. The wound care composition of any one of claims 1-45, the oxidized cellulose and the quaternary ammonium salt present in a wt.% ratio of about 6:1 to about 200:1; the oxidized cellulose and the C_8-12 alkyl 1,2-diol present in a wt.% ratio of about 1.2:1 to about 10:1; and the quaternary ammonium salt and the C_8-12 alkyl 1,2-diol present in a wt.% ratio of 1:50 to about 1:1.

47. The wound care composition of any one of claims 1-46, the oxidized cellulose present in an amount of about 1 wt.% to about 20 wt.%; the quaternary ammonium salt present in an amount of about 0.01 wt.% to about 1 wt.%; the water-soluble polymer present in an amount of about 15 wt.% to about 70 wt.%; the C_8-12 alkyl 1,2-diol present in an amount of about 0.1 wt.% to about 5 wt.%; and a chelator, a chelator salt, or a combination thereof present in an amount of about 0.1 wt.% to about 30 wt.%.

48. The wound care composition of any one of claims 1-47: the oxidized cellulose and the quaternary ammonium salt present in a wt.% ratio of 2000:1 to 1:1; the oxidized cellulose and the C_8-12 alkyl 1,2-diol present in a wt.% ratio of 200:1 to 0.2:1; the oxidized cellulose and the chelator and/or chelator salt present in a wt.% ratio of 200:1 to 0.03:1; the quaternary ammonium salt and the C_8-12 alkyl 1,2-diol present in a wt.% ratio of 1:0.1 to 1:3000; the quaternary ammonium salt and a chelator and/or chelator salt present in a wt.% ratio of 1:0.1 to 1:3000; and the C_8-12 alkyl 1,2-diol and a chelator and/or chelator salt may be present in a wt.% ratio of 1:0.02 to 1:300.

49. The wound care composition of any one of claims 1-48, the oxidized cellulose present in an amount of about 1 wt.% to 20 wt.%; the quaternary ammonium salt present in an amount of about 0.01 wt.% to 1 wt.%; the water-soluble polymer present in an amount of about 15 wt.% to 70 wt.%; a C_8-12 alkyl 1,2-diol present in an amount of about 0.1 wt.% to 5 wt.%; and a chelator, a chelator salt, or a combination thereof present in an amount of about 0.1 wt.% to 30 wt.%.

50. The wound care composition of any one of claims 1-49, the oxidized cellulose and the quaternary ammonium salt may be present in a wt.% ratio of 1:1 to 2000:1; the oxidized cellulose and the C_8-12 alkyl 1,2-diol may be present in a wt.% ratio of 10:1 to 24:1; the oxidized cellulose and the chelator and/or chelator salt may be present in a wt.% ratio 0.03:1 to 2000:1; the quaternary ammonium salt and the C_8-12 alkyl 1,2-diol may be present in a wt.% ratio of 1:50 to 1:1; the quaternary ammonium salt and the chelator and/or chelator salt may be present in a wt.% ratio of 1:300 to 1:0.1; and the C_8-12 alkyl 1,2-diol and the chelator and/or chelator salt may be present in a wt.% ratio of 1:300 to 1:0.02.

51. A wound care article comprising: a wound care composition of any one of claims 1-50.

52. A wound care article comprising: a wound care composition of any one of claims 1-50, wherein the wound care composition is in the form of a free-standing film or a free-standing stack of film, the free-standing stack of film comprising a plurality of free-standing films pressed together.

53. A wound care article comprising: an oxidized cellulose; a quaternary ammonium salt; a C_8-12 alkyl 1,2-diol; and a water-soluble polymer, wherein at least the quaternary ammonium salt, the C_8-12 alkyl 1,2-diol and the water-soluble polymer are in the form of a free-standing film or a free-standing stack of film, the free-standing stack of film comprising a plurality of free-standing films pressed together.

54. The wound care article of any one of claims 51-53, further comprising one or more of: a chelator, a chelator salt, or a combination thereof, a plasticizer, and a collagen, wherein each free-standing film comprises the plasticizer, if present, wherein at least one free-standing film comprises the chelator, a chelator salt, or a combination thereof, if present, and wherein at least one free-standing film comprises collagen, if present.

55. The wound care article of any one of claims 51-54, wherein at least a portion of the oxidized cellulose forms a discontinuous coating in contact with a surface of the free-standing film or the free-standing stack of film.

56. The wound care article of any one of claims 52-55, the free-standing stack of film comprising 2-10 free-standing films pressed together, each free-standing film comprising the water-soluble polymer, at least one free-standing film comprising the quaternary ammonium salt, and at least one free-standing film comprising the C_8-12 alkyl 1,2-diol.

57. The wound care article any one of claims 52-56, at least one free-standing film comprising the oxidized cellulose.

58. The wound care article of any one of claims 52-55, wherein the free-standing film or free- standing stack of film is characterized by thickness of about 3 mil to about 30 mil.

59. The wound care article of any one of claims 51-58, the oxidized cellulose present in an amount from 5 gsm to 200 gsm.

60. The wound care article of any one of claims 51-59, the quaternary ammonium salt present in an amount from 0.05 gsm to 1 gsm.

61. The wound care article of any one of claims 51-60, the C_8-12 alkyl 1,2-diol present in an amount from 1 gsm to 10 gsm.

62. The wound care article of any one of claims 51-61, the water-soluble polymer present in an amount from 100 gsm to 200 gsm.

63. The wound care article of any one of claims 51-62, further comprising a chelator, a chelator salt, or a combination thereof present in an amount of 5 gsm to 40 gsm.

64. The wound care article of any one of claims 51-63, further comprising a plasticizer present in an amount from 50 gsm to 150 gsm.

65. The wound care article of any one of claims 51-64, further comprising a collagen present in an amount from 1 gsm to 25 gsm.

66. A method of preparing a wound care article, the method comprising: providing a wound care composition of any one of claims 1-50; and coating a substrate with the wound care composition to form a layer, and allowing the layer to dry to form a single free-standing film, the method optionally further comprising: forming one or more additional free-standing film according to previous steps, and pressing the single free-standing film and the one or more additional free-standing film together to form a free-standing stack of film.

67. A method of preparing a wound care article of any one of claims 53-65, the method comprising: providing an oxidized cellulose, a quaternary ammonium salt, a C_8-12 alkyl 1,2-diol, and a water-soluble polymer, combining the water-soluble polymer with one or more of the oxidized cellulose, the quaternary ammonium salt, and the C_8-12 alkyl 1,2-diol to form a composition, coating a substrate with the composition to form a layer, and allowing the layer to dry to form a single free-standing film, the method optionally further comprising: forming one or more additional free-standing film according to previous steps, and pressing the single free-standing film and the one or more additional free-standing film together to form a free-standing stack of film, provided that the single free-standing film or the free-standing stack of film comprises the quaternary ammonium salt and the C_8-12 alkyl 1,2-diol, and provided that when the single free-standing film or the free-standing stack excludes the oxidized cellulose, the method further comprises: applying the oxidized cellulose to a surface of the single free-standing film or a surface of the free-standing stack of film.

68. The method of claim 67, combining the quaternary ammonium salt, the C_8-12 alkyl 1,2-diol, the water-soluble polymer, and the oxidized cellulose to form the composition.

69. The method of any one of claims 66-68, further comprising applying oxidized cellulose to the surface of the single free-standing film or the surface of the free-standing stack of film.

70. The method of any one of claims 66-69, wherein allowing the layer to dry comprises heating, reduced pressure, freeze-drying, or a combination thereof.

71. The method of any one of claims 66-70, further comprising: providing a water-soluble substrate, coating the water-soluble substrate with oxidized cellulose to form a water-soluble substrate having a coating of oxidized cellulose thereon, and pressing the water-soluble substrate having the coating of oxidized cellulose thereon to a surface of the single free-standing film or the free-standing stack of film.

72. A method of treating a wound, the method comprising: contacting a wound with a wound care composition of any one of claims 1-50.

73. A method of treating a wound, the method comprising: contacting a wound with a wound care article of any one of claims 51-65.

74. A kit comprising: a wound care composition of any one of claims 1-50, and a set of instructions directing a user to contact a wound with the wound care composition.

75. A kit comprising: a wound care composition of any one of claims 1-50, and a set of instructions directing a user to prepare a wound care article according to any one of claims 66-71.

76. A kit comprising: a wound care article of any one of claims 51-65, and a set of instructions directing a user to contact a wound with the wound care article.